## CONTENTS

October 14, 2009

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>WELCOME, INTRODUCTIONS AND ANNOUNCEMENTS</td>
<td>5</td>
</tr>
<tr>
<td>CHRISTOPHER STALLARD</td>
<td></td>
</tr>
<tr>
<td>CAP UPDATES</td>
<td>7</td>
</tr>
<tr>
<td>CHRISTOPHER STALLARD</td>
<td></td>
</tr>
<tr>
<td>CAP CHARTER AND MEMBERSHIP</td>
<td>29</td>
</tr>
<tr>
<td>CHRISTOPHER STALLARD</td>
<td></td>
</tr>
<tr>
<td>WATER MODELING UPDATE</td>
<td>72</td>
</tr>
<tr>
<td>MORRIS MASLIA</td>
<td></td>
</tr>
<tr>
<td>RECAP OF LAST MEETING</td>
<td>95</td>
</tr>
<tr>
<td>PERRI RUCKART</td>
<td></td>
</tr>
<tr>
<td>FUTURE STUDIES</td>
<td>105</td>
</tr>
<tr>
<td>DMDC DATA</td>
<td>106</td>
</tr>
<tr>
<td>FUNDING</td>
<td>107</td>
</tr>
<tr>
<td>PILOT HEALTH SURVEY</td>
<td>117</td>
</tr>
<tr>
<td>CONGRESSIONAL BRIEFING</td>
<td>135</td>
</tr>
<tr>
<td>CANCER INCIDENCE STUDY</td>
<td>139</td>
</tr>
<tr>
<td>MALE BREAST CANCER</td>
<td>139</td>
</tr>
<tr>
<td>FRANK BOVE</td>
<td></td>
</tr>
<tr>
<td>PERRI RUCKART</td>
<td></td>
</tr>
<tr>
<td>DICK CLAPP</td>
<td></td>
</tr>
<tr>
<td>DEVRA DAVIS</td>
<td></td>
</tr>
<tr>
<td>PRESENTATION AND DISCUSSION ON DISABILITY BENEFITS FOR VETERANS WHO</td>
<td>167</td>
</tr>
<tr>
<td>FILE CLAIMS RELATED TO CAMP LEJEUNE</td>
<td></td>
</tr>
<tr>
<td>THOMAS KNIFFEN, CHIEF OF THE REGULATION STAFF FOR POLICY</td>
<td></td>
</tr>
<tr>
<td>WRAP-UP</td>
<td>220</td>
</tr>
<tr>
<td>CHRISTOPHER STALLARD</td>
<td></td>
</tr>
<tr>
<td>COURT REPORTER’S CERTIFICATE</td>
<td>226</td>
</tr>
</tbody>
</table>
**TRANSCRIPT LEGEND**

The following transcript contains quoted material. Such material is reproduced as read or spoken.

In the following transcript: a dash (--) indicates an unintentional or purposeful interruption of a sentence. An ellipsis ( . . . ) indicates halting speech or an unfinished sentence in dialogue or omission(s) of word(s) when reading written material.

-- (sic) denotes an incorrect usage or pronunciation of a word which is transcribed in its original form as reported.

-- (phonetically) indicates a phonetic spelling of the word if no confirmation of the correct spelling is available.

-- "uh-huh" represents an affirmative response, and "uh-uh" represents a negative response.

-- "*" denotes a spelling based on phonetics, without reference available.

-- "^^" represents inaudible or unintelligible speech or speaker failure, usually failure to use a microphone or multiple speakers speaking simultaneously; also telephonic failure.
PARTICIPANTS

(alphabetically)

BOVE, FRANK, ATSDR
BRIDGES, SANDRA, CAP, CLNC
BYRON, JEFF, COMMUNITY MEMBER
CIBULAS, WILLIAM, ATSDR
CLAPP, RICHARD, SCD, MPH, PROFESSOR
ENSMINGER, JERRY, COMMUNITY MEMBER
GAMACHE, CHRIS
KNIFFEN, TOM, VA
MENARD, ALLEN, COMMUNITY MEMBER
PARTAIN, MIKE, COMMUNITY MEMBER
RUCKART, PERRI, ATSDR
SIMMONS, MARY ANN, NAVY AND MARINE CORPS PUBLIC HEALTH CENTER
SINKS, TOM, ATSDR
SOWELL, ANNE
TOWNSEND, TOM, COMMUNITY MEMBER
P R O C E E D I N G S

(9:00 a.m.)

WELCOME, INTRODUCTIONS AND ANNOUNCEMENTS

MR. STALLARD: Welcome everyone. I’m told by Ray
this is our 17th --

COURT REPORTER: Fourteenth.

MR. STALLARD: Fourteenth, I stand corrected.

Fourteenth CAP meeting. And so what I would like to
do is start things off a little different this time.
Whenever we start I sort of go over the operating
and guiding principles and whatnot and then
introductions. But today we’re going to start a
little differently in many ways.

We’re going to start with a moment of silence
for our fallen comrade and CAP member, Denita
McCall, who expired during our last meeting, July
8th. Many of you remember her. She was ardent and
passionate about this CAP. And so if we would,
please just take a moment. Here’s her own
handwriting of her name card up there, and let’s
just reflect on what she brought to us and her life.
(Whereupon, a moment of silence in honor of Denita}
McCall ensued.)

**MR. STALLARD:** Okay. So in the past to sort of lay out --

Ray knows you well enough to capture your name while you’re doing this, but I would like for you to tell me what are our guiding principles rather than me telling you. We’ve been doing this 14 times now, so I think it’s, I’d like to hear from you. How do we operate here? What are the guiding principles that govern our interactions?

**MR. ENSMINGER:** No personal attacks.

**MR. STALLARD:** Okay, thank you, no personal attacks.

What else?

**MR. ENSMINGER:** Try to stay on the issue at hand.

**MR. STALLARD:** Stay on the issue at hand.

What else?

**DR. CLAPP:** No talking over one another.

**MR. STALLARD:** Thank you.

**MR. BYRON:** Say your name before you speak, Jeff Byron.

**MR. STALLARD:** Thank you very much. Say your name before you speak.
MR. ENSMINGER: That was for him over there. He knows all of us now, so.

MR. STALLARD: Yes, he does. Anything else?

MS. BRIDGES (by telephone): Respect.

MR. STALLARD: Respect, from Sandy. Thank you.

Just a few things that we might not have covered. When you speak, push the microphone down to engage it, and you’ll see the red light. When you’re finished, please turn it off. The audience is here to listen and observe. They may be asked by the CAP panel, by the members, to respond if there’s someone that you know in the audience who has the expertise or the wherewithal and desire and choice to respond to any questions that you might have for them.

CAP UPDATES

So, likewise, I would like to do something a little bit different this time in terms of introductions. In the past it’s been pretty curt, you know, my name, CAP member. I’d like to hear a little bit more. Who you are, why are you a member of this CAP, and what has transpired since the last
meeting. What are some of the things that you have
done and that the CAP is doing since our last
meeting to get a sense of between meetings what’s
going on with the CAP activities. So, we’ll start
in no particular order.

MR. BYRON: Hi, this is Jeff Byron from Cincinnati,
Ohio. I guess one of the major reasons I’m a CAP
member is because I believe that if you’re going to
ask someone for help, you have to be willing to help
yourself and that who can guide your destiny better
than you.

And a lot of the reasons that I got involved is
that I could see from the very get-go that they only
wanted to contact the people who had children in
utero, and I wanted to change that. I wanted to
make sure that all Marines who were exposed had the
opportunity to be told and make the decisions for
their family members, you know, in an educated
manner.

So they started with Jerry Ensminger and the
website, The Few, the Proud, the Forgotten. And I
believe we have over 1,360 members now, and I
believe now the government has contacted over
140,000 Marine Corps veterans. So I think we’ve
been very successful there. Since the last CAP
meeting, I went to Washington to attend a meeting on
veterans affairs concerning Camp Lejeune and other
exposures that occurred in the military. It wasn’t
just on Camp Lejeune.

I spoke to my senator, Brown from Ohio, and I
told him that we had a lack of VA participation in
the CAP meeting, and I made a motion to bring a VA
representative on the CAP so that when we’re
researching the future studies for mortality and
cancer incidence, that we wouldn’t have to wait as
long for databases that the VA holds. And as you
know, now we have someone here from the VA to give a
presentation so I think that’s one accomplishment
we’ve been able to do and is important for the
future of what we’re doing here.

MR. STALLARD: Thank you, Jeff.

MR. PARTAIN: Go ahead, Tom.

MR. STALLARD: Yeah, go ahead.

MR. TOWNSEND (by Telephone): I’ve been a CAP member
since its inception along with Jerry. I’ve been working on finding the documentation since 1990, since 1999, when I first found out about the survey of the 17,000 women at Camp Lejeune. I’ve lost my wife. I’ve lost my child.

I’ve been recently working on directing my activity towards the Veterans Administration. I have been in contact with the Under Secretary for Benefits and have been telling him directly what’s going on, that there’s, the Veterans Administration is a very closed society.

I’m a disabled veteran myself and can get good service from the medical facilities, but the when dealing with a like this is very difficult. And I think the fact that the VA has been pushed on by several members is productive. I think there’s a great number of veterans out there that have been injured are still unknowing of the cause of their injury so I’m pleased that this is going forward.

MR. STALLARD: Thank you, Tom.

Sandy, do you want to go next, please?

MS. BRIDGES (by Telephone): Sure. I’ve been a
member for almost ten years now. And what I’ve
tried to do is to help everyone involved here on our
CAP as well as to inform and get lists and data and
try to help people, dependents, that are in a
similar situation that we are. My children have
been affected and a lot of my close friends.

MR. STALLARD: Thank you, Sandy.

MS. BRIDGES (by Telephone): Thank you.

MS. RUCKART: Allen.

MR. STALLARD: Allen, yes, take care of the phone
call-ins, please, so would you share?

MR. MENARD (by Telephone): Sure. I’ve been a CAP
member since last year, and what I’ve been doing
since the last CAP meeting is I’ve been talking with
people around Wisconsin and the neighboring states.
And I’ve been helping them with their VA claims and
stuff like that.

And I’ve been contacting, I’ve been on Senator
Feingold and finally he co-sponsored. I’ve been
trying to get Senator Kohl to co-sponsor the Camp
Lejeune, Caring for Camp Lejeune Act. And I’ve also
been trying to get the neighboring state senators
around here to do that and been getting a lot of phone calls from vets wanting information and help. And basically, that’s what I’ve been doing.

MR. STALLARD: How has that been for you working with the VA in Wisconsin?

MR. MENARD (by Telephone): It’s been actually pretty good, and to me I found out that the VA office, they don’t know hardly anything as far as this Camp Lejeune thing is concerned. They might be finding out more now, but their knowledge of everything that’s going on in regards to Camp Lejeune has been nothing.

In fact, what I tell them is all news to them. And I think the VA needs to do a lot better job in informing their field officers, however they say that, to what’s going on here and the sensitivity to the, you know, to the issue at hand.

MR. STALLARD: Thank you, Allen.

Mike.

MR. PARTAIN: This is Mike Partain. I joined the CAP in December 2007, after I was diagnosed with male breast cancer. I’m one of the in utero
children who was born at the base back in 1968. Pretty much we’re working to, as everyone said, get the word out. I found out by chance seeing a news report shortly after I was diagnosed.

One of the big things we’re working on right now is trying to get support for S.B. 1518, which is the Caring for Camp Lejeune Veterans Act, which was introduced by Senator Burr. And I understand there’s a companion bill in the House.

Do you know the number over there, Jerry?

MR. ENSMINGER: No.

MR. PARTAIN: A companion bill in the House for this, so this is the way we get VA assistance for the people that were affected at Camp Lejeune. And, of course, recently we had a major news media event concerning the other known breast cancer cases we’ve been finding over the past two years starting with me and now we’re up to 49 men. The last man I was contacted last night was diagnosed yesterday with male breast cancer and e-mailed us to let us know that he was at Camp Lejeune and now has male breast cancer.
As usual with anything, the more attention we get on it, the more involved in it, the more people become aware and the more we can talk about this issue and get a resolution.

MR. STALLARD: Let me just clarify. Before Mike joined this CAP, were we looking at male breast cancer at all?

DR. BOVE: We were looking at all cancers, including trying to look at breast cancer. We were looking at every cancer in the health survey study and the mortality study that we were proposing. But trying to look at male breast cancer in a mortality study would be extremely difficult.

It’s not a very fatal cancer and the population we will be studying is relatively young, so it’s likely we’d find very few deaths from breast cancer among men so that the mortality study is not the best vehicle, at this point anyway, to evaluate breast cancer. The health survey is a better vehicle. We can talk more about other options later today.

MR. STALLARD: Thank you.
So what happened since your CNN presentation?

You had, I think 25 or so?

MR. PARTAIN: Well, when we started the CNN --
actually, going into June of this year I had found
roughly about ten men. And then there was an
article in the St. Pete Times down in Florida. That
article produced ten additional cases within like a
week and a half.

And then shortly after that article, CNN
contacted us expressing interest in the male breast
cancer issue that we’ve identified. And when CNN
going to air their program, we had 20 cases, and now
we’re up to 49. So in the space of what, two and a
half weeks, three weeks, we’ve doubled the number
and approaching tripling the number.

DR. BOVE: It was also in “NBC Nightly News,” was it
Friday?

MR. PARTAIN: Yeah, Thursday night, NBC, and my
understanding CNN ran it over the weekend, and I
think there was a small blurb about the hearing last
week on ABC. We also had a hearing where we were
able to discuss the Camp Lejeune issue in the Senate
Veterans Affairs Committee from bringing the issue up to the Senate.

MR. STALLARD: Perhaps during today we’ll get some feedback on how that went. Thank you.

Jerry.

MR. ENSMINGER: I’m Jerry Ensminger. I’m a retired Marine. I lost my daughter Janie, who was the only one of my four children that was conceived or had anything to do with her birth at Camp Lejeune. She was the only one. When she was six, she was diagnosed with acute lymphocytic leukemia, and she died at the age of nine.

I’ve been involved in this situation from the beginning. I realized, you know, Tom Townsend and I worked very close at hand at digging up information. And the more that I looked, the more dismayed I became as I saw internal e-mails from Camp Lejeune and Norfolk and Headquarters Marine Corps. The misconduct that was taking place in regards to the military and even some of our other federal agencies was, to say the least, disheartening.

And my goal has been on this CAP is to be, I
don’t know, the mouthpiece for the community as a conduit to assist ATSDR. And, you know, ATSDR has their problems. Everybody realizes that. But the Department of Defense, especially Department of the Navy and the Marine Corps, have been less than forthcoming with ATSDR, and they’ve had a lot of problems dealing with these folks.

I mean from the lack of providing data to incorrect data they were being provided for their work. Like I said that’s not to say that some people at ATSDR didn’t screw up either, but, you know, there’s enough blame to go around to everybody in this situation. And I became very politically active, and I’m working my butt off on Capitol Hill to get political support and backing for this issue.

When you boil this thing down to the facts, it is quite clear. We had Camp Lejeune, which is a known superfund site, documented. It’s an NPL site; one of the worst contamination sites in the country. Number two, we know we had human exposures at Camp Lejeune. It’s documented. So where the hell’s the question at here?
We know that the Marine Corps and the Department of the Navy had regulations that would have avoided this. They didn’t follow them. And now nobody wants to talk about those. They talk around them. Well, the day is coming, the day’s coming. We’re going to have to address these regulations that you all had in place, and we’re not going to talk around them. We’re going to talk right at them, like the BUMED and the base orders.

I mean, I saw a motion to dismiss presented by the attorneys representing the Department of the Navy in a court case. It is absolutely ludicrous. They talked around everything they didn’t want to confront in those regulations, but they didn’t confront the meat of the regulations as far as the standard of care and the duty that was created by those documents.

And, you know, right now we’ve got an issue going with the Department of the Navy about funding. Where’s the money? Like the old commercial, where’s the beef; where’s the money? ATSDR is statutorily required to do these investigations at NPL sites.
And the people responsible for the contamination are responsible for funding their activities. Title 42 requires it. Now, October 1st was awhile ago. We need to find out today where the money is.

MR. STALLARD: Thank you, Jerry.

You, too, Perri.

MS. RUCKART: Perri Ruckart, ATSDR.

CAPTIONER (by Telephone): What is ATSDR?

MS. RUCKART: Is that the closed captioner?

CAPTIONER (by Telephone): Yes. What is ATSDR and what does Cap mean? I’m sorry for the ignorance.

MS. RUCKART: Who’s that? Is that the closed captioner? Who is that who is asking the question?

CAPTIONER (by Telephone): Yes, I am the closed captioner.

MS. RUCKART: ATSDR, Agency for Toxic Substances and Disease Registry; we’re the meeting host. And the CAP is the Camp Lejeune Community Assistance Panel.

MR. STALLARD: And there was a question of the NPL site or --

CAPTIONER (by Telephone): (Indiscernible)

MS. RUCKART: Community Assistance Panel.
CAPTIONER (by Telephone): Thank you very much, ma’am, and I apologize.

MS. RUCKART: Okay, no problem.

Perri Ruckart, ATSDR. I’ve been working on the Camp Lejeune project since 2003. Do you want me to talk about what I’ve been doing?

MR. STALLARD: I want you to say what we were talking about -- well, you’re here because you’re part of ATSDR, number one, so that’s (indiscernible). What has happened since the last meeting that you contributed to the CAP, or do you want to defer that to your update?

MS. RUCKART: Well, yeah, because I’ll be having a whole section on that.

MR. STALLARD: Frank.

DR. BOVE: My name is Frank Bove. I’m a senior epidemiologist, Division of Health Studies, ATSDR. I don’t know how long I’ve been involved in this issue. Peripherally involved with this small for gestational age study, so I guess it goes way back. And I will update you.

MR. STALLARD: Okay, thank you.
DR. SINKS: I’m Tom Sinks. I’m the Deputy Director of the National Center for Environmental Health and ATSDR, and you folks seem to welcome me enough that you let me sit at the table. I’m not a member of the CAP, but I always enjoy the interactions and want to keep the communications as open as possible between everybody who’s interested in Camp Lejeune.

MR. STALLARD: Thank you.

MS. SIMMONS: I’m Mary Ann Simmons, Navy-Marine Corps Public Health Center. I’ve been attending the CAP since it started and became a member I’m not sure when, awhile back, at the request of the CAP members that they wanted a DOD representative. And my duties here as I see them is to be a good liaison between the CAP and DOD.

MR. STALLARD: Okay, thank you.

MR. BYRON: One minute. What have you done since the last meeting? Sorry.

MS. SIMMONS: That’s okay. I forgot. Working on many different issues, trying, I’ve actually tried to watch the hearing the other day, but I couldn’t get it to stream on my video at work, and just
trying to keep up with the news because there’s always lots going on with this project.

MR. STALLARD: So just to satisfy my curiosity I suppose, as the liaison to DOD, do you communicate and provide information to the CAP members?

MS. SIMMONS: When there’s something that they requested. What I’ve usually done is provide it to Perri and ask her to send it out to the rest of the CAP members.

DR. CLAPP: My name is Dick Clapp. I guess my involvement in the CAP goes back actually to college where a good friend and, not roommate but I lived next door to him, went into the Marines and died in Viet Nam, and this was in 1968, but he went through Camp Lejeune.

And then subsequent to that I studied the Agent Orange health effects and on vets as in the early ’80s and got involved deeply with on vets at that point, testified in front of two committees of Congress and then went to the VA and presented some results of some work that we had done in Massachusetts, and, you know, actually to this day
continue to stay involved in the Agent Orange issues, dioxin especially.

And then more recently got involved with a program that would be useful in public health that we call the Boston Environmental Hazard Center, which was a VA-sponsored and VA-housed research project on health effects of exposures in the Persian Gulf War on veterans. And we did a study of cancer in Massachusetts Persian Gulf War veterans.

And then Frank called me, I think in probably the winter of 2003 or thereabouts, and Frank’s an old friend of mine, and he said we’re setting up this CAP. We need an epidemiologist among others, so I said sure. And I got involved I think February in 2006 was my first, I probably got involved in the winter of 2006 and then February was the first meeting.

And it’s been an amazing process, an amazing experience for me personally and professionally. The reason I’m here I think is because of the people sitting around this table and on the phone and one departed member. And so I’ll continue. I’m
planning to retire next June from my job at the BU School of Public Health, but I don’t think I can retire from this.

I guess the other question was what’s happened since the last meeting. I’ve been interviewed on CNN, an interview for about 20 minutes, and I think they used about three seconds, but that’s how it goes. I talked to, briefly, to three members on the NRC Committee, the National Research Council Committee, Dr. Jay Nuckols, Dr. David Savitz, and Dr. Bruce Lanphear, two of them in person and one on the phone.

And it was really in passing. It was because they were, either I was at a meeting that they were at or one of them, David Savitz, came to a meeting at BU that I happened to, I wasn’t part of the meeting, but I knew he was coming so had further conversations with them about what they were doing and what they thought they were doing. And I think what I said at the last meeting here about the naiveté I would still hold to.

I’ve also gotten phone calls from a number of
vets, phone calls and e-mails from a number of vets, some asking for clinical advice. How do I get diagnosed for this or who can treat this. I’d have to say I guess that’s because my name has been attached to this. I’m not a clinician. I don’t really have any way of answering those questions. I tend to refer them to their local medical facility or the local teaching hospital if they have one.

And I also got a call or an e-mail rather from a Senate staff member before the hearings last week. I think those are the things. Oh, and I teach about this stuff. I have to say that this story, this unfolding research effort as well as the human part of this story, students are fascinated by this, and students really want to know what’s going on. And so from the point of view of academic this is rich material so I talk about it in my class.

MR. STALLARD: Dick as well can use your input in the next dialogue we’re going to have about what is a CAP, you know, what’s it supposed to do. I have you until ten to go through this process of introductions, welcome and then talk about how we’re
structured and whatnot.

But Dr. Clapp, I’d like to ask about the NRC. Didn’t you put together a, I don’t know if you call it a rebuttal, but you had other colleagues who saw things differently and to that report. What has transpired since then?

DR. CLAPP: Well, with the five of us, which we did at the request of CAP members, five of us, only one of us was a member of the CAP but my four colleagues drafted and redrafted and finally signed a statement that was I guess you’d say it was a rebuttal or at least we took issue with the, especially the epidemiologic part of the NRC report, how they reviewed the scientific information about trichloroethylene and perchloroethylene, for example. And there’s been nothing new on that.

Dr. Nuckols asked me why don’t we have a debate. Why don’t the people on the NRC who are interested and the five of us that signed that statement have a public debate somewhere at some conference or somehow. And that’s still on the table, I guess. And I think I’m pretty sure at
least two or three of the people who signed that rebuttal would do it, you know, would appear at some event.

I talked with Dr. Savitz about us having a point-counterpoint exchange in a journal like something called Environmental Health Perspectives, which is, you know, like it sounds, an environmental health journal that’s published by a federal agency, and we may do that. Dr. Savitz is personally not interested, but he said he would talk to some other members of the NRC, that maybe they would agree to do that. And in that case I think we might carry the conversation forward.

This is sort of in the point of what’s the purpose of scientific studies after all, and when is uncertainty a cause for no action as opposed to some action, and what are those kinds of actions. I guess that’s basically the summary of that conversation. Watch out. I’m a professor. I’ll go on for an hour if you let me. The issue about science and how it’s used is at the root of this I think, and/or misused is at the root of this. So
there’s a lot here to talk about.

MR. STALLARD: Thank you.

MR. PARTAIN: Dr. Clapp, as a member of the CAP, I mean, you mentioned that Dr. Nuckols expressed an interest maybe in doing a debate. I would like to see that and what better form to do it here at a CAP meeting or at ATSDR since they are the statutory agency required to do the health assessments and to NPL sites such as Camp Lejeune.

MR. STALLARD: Well, we can talk about that.

Tom, did you have something?

DR. SINKS: Yeah, I just wanted to add that since the last CAP meeting we had said that we would provide a written set of plans for our work on Camp Lejeune following the NRC report.

Jerry, you tried to hold me to a pretty tight deadline. I think we were two weeks ahead in terms of getting that report out. So we did get that report out. We did take, we asked the CAP to get us written comments, which the CAP did.

We also had the comments from Dick Clapp, and we received some from the NRDC, National Research
and Defense Council. We used all of that in our
decision process as well as the comments from our
staff and put that out. And I think you all have
that.

MR. STALLARD: Right, thank you.

Any my name is Christopher Stallard, and I’ve
been with the CAP since the inception based on the
meeting that I facilitated with the expert panel
that essentially said that future studies were
warranted and then therefore this CAP was
established.

Before we move on to talk about the CAP having
been established and how it’s structured, I would
like to point out to those of you on the phone who
might not be able to see, that we have this candle
lit and flowers that CAP members brought in for
Denita, just so you’re aware visually of what we
have in the room.

CAP CHARTER AND MEMBERSHIP

So we had an expert panel that said future
studies are warranted and said, okay, we need to
establish a CAP to do that, and shazam, lo and
behold, we all came together and here we are. That
was going on three years ago I believe.

We never really, I think, CAPs are different
all over the world where they exist. They can be
highly structured, or they can be organic in nature.
And so what I’d like to do is have a dialogue about
this CAP: what’s working well, what’s not working
well. Is it structured to do what you think it
needs to be accomplished, and if it’s not, how would
we structure it to be more effective to accomplish
its goals.

So I would like for this to be a dialogue of
sorts, and I’ll capture your ideas about it. Now,
Frank, I think, has a lot of experience in working
with CAPs. To me, the A in CAP is assistance. So
the reason we’re together is to provide assistance
to whom is the question I have. To whom?

MR. ENSMINGER: First word, community.

MR. STALLARD: The community, right. And so we all,
by being members of it, have a responsibility
because we choose to be here to provide that
assistance. And so are we structured in the right
way to do that?

CAPTIONER (by Telephone): This is Tom Mitchell. My name is Tom Mitchell. I am one of six kids that lived at CL and all of us are sick. I have been dealing with Channel Four in my area for a CP broadcast and interview. I hope I get more than three. My mother was pregnant with me at Camp Lejeune when I was born.

One moment, please.

MR. STALLARD: Thank you for sharing.

MR. PARTAIN: And closed captioner, if you’d go ahead and send me an e-mail, I’d appreciate it. I’ll talk to you after the meeting.

CAPTIONER (by Telephone): I’m sorry. I’m not sure I understand. I’ve been speaking for Tom Mitchell, and I’m so confused here. He is typing as they are speaking. I’m not sure if I should break in and interrupt.

MR. PARTAIN: I misunderstood you.

MR. ENSMINGER: Ask her if this thing is closed captioned.

MR. STALLARD: First of all, thank you for being on
the phone. We need to kind of clarify, who is Tom
Mitchell that’s calling in, and are you getting
closed captioning on the broadcast that’s being sent
to you?

CAPTIONER (by Telephone): I’m not sure who Tom
Mitchell is. I work for a company ^ Colorado.
(Indiscernible)

MR. STALLARD: Excellent, thank you. I think now we
have a better understanding.

CAPTIONER (by Telephone): I’m sorry, and I’m a
little confused, too, because I have like over ^.

MR. STALLARD: No, no, no, it’s all about
understanding and communication. I think your role
for the purposes of this meeting would be most
effective if you would capture the questions that
come in to you, and then hold them and share them at
the end electronically with the people that you’re
working with, the CAP members. And then we will
address those questions and you can respond to them.

Hold on just a minute, and I’ll have Perri provide
some additional information. But this is not the
forum for us to provide responses to the general
public who might be listening in, real-time.

**MS. RUCKART:** So, closed captioner, you can just e-mail those questions to me. I’m the person who sent you the e-mail requesting the service that you provide. So if you still have that e-mail requesting that, you can send all your questions at the end back to me, Perri Ruckart.

**CAPTIONER (by Telephone):** Okay, (inaudible).

**MS. RUCKART:** Whatever questions you’re getting in from the public, you can just send them to me at the end, and then we can address them. But you can ask the people to provide you with some contact information. That would be helpful.

**CAPTIONER (by Telephone):** It would be helpful for me, too, ^ contact information and they can send it to you directly at ^. That’s not actually our role ^.

**MS. RUCKART:** Yes, they can submit it if they go to our ATSDR Camp Lejeune website which is where they should be right now to see the closed captioning link. We have contact information on there. They can submit their questions directly to us, and we
As Christopher was saying, this is not really the forum for that, so if anyone is watching this, either streaming on the internet or looking at the closed captioning, please, if you have questions just send them to the ATSDR Camp Lejeune mailbox or CDC info. You’ll find that information on our ATSDR Camp Lejeune web page, which is the website you’re on right now to view and learn about this meeting.

MR. PARTAIN: And unfortunately, we don’t have the time to address individual questions here, but as a member of the CAP, if anyone out there has a question to us, they can also go to our website, The Few, the Proud, the Forgotten, and send an e-mail to either, Jeff, myself or Jerry, and we’ll be happy to answer that question for you.

CAPTIONER (by Telephone): ^ Or would you like me to hold off ^.

MS. RUCKART: I think we’ll just have them send the questions directly to us at ATSDR CDC Info or they can contact the community members at that website, The Few, the Proud, the Forgotten. So if anyone is
watching this, listening to this, reading it through closed captioning, we’re happy to answer questions, but please do it through the ATSDR e-mail, CDC Info or if you have questions for the community directly to The Few, the Proud, the Forgotten website. Thank you.

CAPTIONER (by Telephone): Thank you very much. I appreciate it.

MR. STALLARD: Thank you.

MR. PARTAIN: Actually, it’s a good thing. People want to interact and --

MR. STALLARD: Yes, that’s great. If you have any more questions, please don’t hesitate to ask. It’s all right.

So let’s get now to structure. Is this an issue for this group? Is it something we need to discuss?

MR. ENSMINGER: I don’t have a problem with it.

Jerry Ensminger. Somebody got their hackles raised about wanting to replace people that had left the CAP. I mean, we’ve got people that are sick, that can’t participate. We’ve got people that have other
family members that get sick, and they can’t really dedicate a lot of time to this. We started this CAP with seven community members and two experts, Dr. Clapp and Dr. Fisher.

DR. CLAPP: And Rennix.

MR. ENSMINGER: Well, he was part of the DOD. The DOD when we offered them to, after the first meeting we realized that we were having to go out to the audience to get responses, and I asked that the CAP would allow two members from the Department of Defense on.

But it’s still a messenger service. They haven’t put anybody on here from Headquarters Marine Corps after we got rid of the lawyer off of the CAP. We still don’t have anybody representing Headquarters Marine Corps at the table, but that’s their call. So be it.

But as far as us keeping our original numbers filled, who is it that has the problem with this? I mean, every time we go to submit a new name, we get push back. Where’s it coming from? Let’s get it out. Come on.
MR. STALLARD: We missed something on our operating guidelines. That would be openness and transparency.

MR. ENSMINGER: Transparency.

MR. STALLARD: And let’s just put in I like to operate under that, honesty. So the question is who has a problem with it and --

MS. SIMMONS: This is Mary Ann Simmons from DOD and the Navy. I’m not sure what problem that you’ve seen. What I would suggest, I haven’t been on a CAP before, been familiar with those, but I have been involved with restoration advisory boards which, Jerry, you’re on Camp Lejeune, and they’re much more structured.

And I’m not saying this is what we need, but that’s what we’re used to, at least in DOD, where there’s a process for putting new people on, how long people stay, what the purpose of the group is, et cetera, et cetera. So the only, I think that would be personally, that would be a good thing for this group. Again, that’s what DOD’s used to.

The only other thing I know about the push back
is when I believe somebody nominated Mr. Menard to be on. And I just simply asked who, where he was from because the name wasn’t familiar to me, and that was it. I mean, I don’t think that was a push back. That was just a question. And perhaps if we had a structure for nominating new people that that wouldn’t have been perceived as a push back.

MR. STALLARD: Thank you, Mary Ann.

MR. ENSMINGER: What kind of structure are you talking about?

MS. SIMMONS: You know, I’m not sure. Again, we could, my familiarity is with the Restoration Advisory Board. Perhaps Frank, Scott or Perri has some other information about other CAPs. I’m not sure how these are typically structured or chartered or whatever the right word is, so maybe Frank.

DR. BOVE: That was mentioned to me before about the Restoration. What is it called?

MS. SIMMONS: Advisory Board.

DR. BOVE: Maybe it would be interesting to find out because I’ve been asked that, too, why isn’t the CAP run like the Restoration Advisory Board? And I said
it’s because it’s a different entity altogether.
But I would be interested just for my own education
how that is structured. How is that structured, and
then I’ll tell you more what I think about the CAP.

**MS. SIMMONS:** Okay. I can provide you -- or you
probably could, too -- charters from different ones.
And basically they put out the purpose of, the
Restoration Advisory Board in this case, who is
eligible to be members. What the process is to get
new members, et cetera, et cetera. The purpose of
the meetings. How do you know you’re through, those
sorts of things.

**DR. BOVE:** That’s a FACA? It’s under the FACA law?
You said it’s advisory committee so it must be.

**MS. SIMMONS:** And I just know that’s part of our
clean-up process. It’s just part of the DOD’s
clean-up process, and everybody in DOD who sites on
a superfund site is supposed to have a RAB.

**MR. STALLARD:** That’s an interesting question. How
do you know when you’re done?

**MR. TOWNSEND (by Telephone):** This is Tom Townsend.
I’ve got an inquiry here.
MR. STALLARD: Well, go ahead, Tom, ask it.

MR. TOWNSEND (by Telephone): I think our CAP works exceedingly well. It’s comprised of victims. We know, I think we know where we’re going. I think we know who has the information. I think we know who has to make the decision, who has to make some recompense.

I don’t think that I’m particularly interested in a -- we can certainly write down how we do our business, but we seem to do our business as a group of individuals that have a personal role in this situation. Jerry and I and all the rest, Mike and other folks all have contributed in their own way to moving this issue forward.

Some of us, I don’t show up because it’s difficult for me to walk, and I don’t want to hoof around the Atlanta airport and CDC so I participate this way. But I’m continuing to participate in my own fashion as a family member that has lost two of his folks and myself.

And I’m still looking for material, like the 36 FOIA requests I got. So I’m still involved in doing
what I do, and I don’t think if you want me, if any
of us can tell, can state on a piece of paper how we
operate and all that kind of junk. But I don’t
think we have to be a structured, definitively
structured group. I think we’re doing very well as
we are.

MR. ENSMINGER: Hey, Tom?

MR. STALLARD: Thank you, Tom.

MR. ENSMINGER: This is Jerry. Another thing is
with this CAP, yeah, we have agenda items that the
CAP and ATSDR work together putting together for
these meetings. But, you know, let’s face it, every
time we come to one of these meetings there’s some
kind of damn crisis going on.

It’s like playing wack-a-mole, you know. It’s
either the Department of the Navy’s withholding the
funding, or we find out that there’s some database
out there that hasn’t been provided to Morris and
his group. There’s always some crisis at every
meeting. It never fails. How many times has it
been now on the funding? What’s this, the third
time that the Department of the Navy’s threatened
withholding the funding?

So we need some cooperation from the other
side, and they’re creating these crises. And it’s
nothing but a delaying factor that’s built into
their system. Keep pushing this thing and kicking
this can down the road a little further.

MR. STALLARD: Thank you, Jerry.

Frank, did you have something?

DR. BOVE: Well, I would like to mention some of the
issues that I’ve heard, and again, I’m going to be
the messenger here. I’m not going to let you know
right away where I stand on this, but just give you
an idea of what kinds of things I’ve heard
internally and externally – some of the issues that
have been raised.

One is the issue of how representative the CAP
is. There is another group, for example, that is
not being represented on the CAP. So that’s been
raised. It’s been raised internally and externally.

Some CAPs are representative in the sense that
they try to actually get a good cross-section of the
particular community. That’s sometimes easier when
the site is in a community and the community’s not
dispersed all over the place but instead the people
affected live in that community. So they try to get
the librarian and someone from church groups and so
on and so forth, all the major players in town
politics, and someone would represent city hall.
Some CAPs have been organized that way, and
sometimes they work, and sometimes they don’t.

Other CAPs have instead, been more like this
CAP, consisting of members who are, what I would
call, key informants or people who have been
actively involved, and they make up the CAP. And
sometimes they work, and sometimes they don’t work
as well. This kind of CAP involves the people who
do the research and the people who are extremely
interested in the issues.

So there’s no blueprint to what works. We’re
not a FACA. That’s why we call ourselves an
assistance panel to avoid all the FACA regulations
because they get in the way. We want, and what we
hope to get is more on the model of what’s been
called community-based participatory research or
participatory action research.

Community-based Participatory Research basically means that the community, the affected community is involved at the ground floor in the decision making, or at least provides input into the decision making if not making the decisions themselves in what happens in that community and then takes the ball after agencies like us disappear and carry it through.

So that’s sort of the model, I think, that was in the minds of some people at ATSDR when the CAP was first introduced. But there are differences of opinion within my agency. So that’s one issue. Is it representative or should it be representative or should it just involve what we call the key people in that community who are affected and do the research and do the work.

So that’s one issue. The other issue is what does the CAP deal with? Now, we’ve all agreed from day one that the main issue was to inform us on how to do our work in terms of future studies, both the water modeling effort and the mortality study, the
health survey, the cancer incidence study, even our
current studies, any input into how we carry those
studies out. That was the charge that comes out of
that science panel in 2005, and I think the CAP has
addressed those issues very well.

Part of doing the future studies, in particular
the health survey, but in general it’s also to help
us communicate about these studies and about the
water modeling research to the general public and to
the affected population. So that was part of the
charge, if you will. We didn’t have an official
charge. That was our, but I think that that was,
actually, we did call it a charge back then so I
think we did have an official charge.

I think some people internally don’t think we
have an official charge, but I remember that that
was pretty clearly stated. So I think we do have an
official charge. The question is, is that the right
charge or -- and the other issue is have we stayed
on the charge or have we strayed into other issues
which I’ve heard people say.

For example, BUMEDs, I mean, that’s not
necessarily connected to future studies, for example.

MR. BYRON: But it has to do with the last --

DR. BOVE: I’m just saying --

MR. BYRON: -- item, honesty.

DR. BOVE: Right, I’m not pushing this position. I am just bringing up these issues so we can discuss them so at least they’ve been brought up. The people who raised these issues with me are not here to raise them. They chose not to bring them up, so instead I will raise them.

So the other issue is, well, for example, the VA denial of benefits. The VA providing data for us in our future studies is one thing. VA denial of benefits is another issue. Is that an appropriate issue for the CAP to deal with? Some people would raise that. So these are the kinds of things that have been raised.

My feeling, for what it’s worth, is I think the CAP is working very well, that the word has gotten out, and I think that you’ve helped us a great deal on the water modeling effort finding documents.
You’ve critiqued the NRC reports and that I think was helpful. There are various things that the CAP has done.

I do think it would be great if we could get someone from the other website to be a part of this because I think that because they’re not, it’s been difficult sometimes to get them to understand what we’re doing, but I understand the issues there. And so if it can’t happen, it can’t happen.

In an ideal world all the groups would be working together spreading the message and working together in one coalition, but that doesn’t always happen and hasn’t happened here. And so that may be a drawback, but I think it’s been working pretty well. That’s my opinion.

MR. BYRON: Well, this is Jeff, and I’d like to speak to the matter of representation as you were talking about. First off, there were two CAP members from the other group that were here and present, and they declined to attend any longer because they’re interested more in compensation versus healthcare studies. Now, I think all the
members that are here today are interested in the future studies.

I believe we’re wasting our time talking about structure because really what we’re doing is we’re addressing those few individuals who believe that they’re not represented here today. And they think that the veterans are only representing veterans. That could be the furthest thing from the truth because I’m here representing my family and the two individuals who are sick in my family are dependent daughters, both of them. One has a bone marrow disease, the other has multiple issues, and that’s why she’s in the in utero study.

So I have never brought up my medical issues here as a veteran, although I support bringing the VA in. I’m the one who made the motion to bring them here. As a matter of fact I wish they were sitting at the table because they have been asked to be a CAP member. There was a motion made. It was seconded, and everybody asked them to be, and we’ll wait for that presentation.

But to this matter of who’s being represented
and who isn’t being represented, all the victims are represented, military, civilian, dependent family members, male, female, children, adults. And I resent the fact that anyone would imply that our group does not represent everyone.

MR. STALLARD: Just as a, before we continue on, I’m going to carry this through to our break at 10:15.

MR. BYRON: And real quick, I’d like to say that I’d like to get on to where we’re at in the mortality and cancer incidence instead of rehashing how people outside of the group are unhappy because I would have liked them to be here, too. But they are the ones who declined to be here. They weren’t asked to leave.

DR. BOVE: The issue of structure, the issue of who should be represented on the CAP, is not necessarily coming from the group you’re talking about. Just keep that in mind. It’s coming from other places as well, including within ATSDR.

MR. PARTAIN: Well, but the structure, I mean, look at the, we have three members who are veterans. We have two members who are dependents, and we
represent pretty much the cross-section of the community. We don’t have a member who was employed on the base. That’s the only group that’s really not represented on the CAP. So spectrally we are representing everybody who’s in the affected community. And, I mean, functionality, we do function. We police and monitor ourselves, you know, the people that we nominate and vote on as a member of the community are functional and are working. So why fix something that’s not broken?

And on the subject of straying off, like you mentioned the BUMEDs and the history and everything, you know, my degree’s in history. I’m not an epidemiologist or a scientist, but I am degreed in history, and you cannot know where you’re going in the future if you don’t know where you’ve been in the past.

And I think you can agree with me the research that we have been doing uncovering the documents has led to a lot of revelations, for example, the interconnections between Hadnot Point and Holcomb Boulevard which affects a great number of people who
otherwise didn’t know they were exposed. So, yeah, we’re going to go on some tangents, but they’re all interconnected. It all has merit and all has purpose.

**MR. ENSMINGER:** With that being said -- this is Jerry Ensminger -- with that being said I’m going to nominate Terri Huntley to the CAP right now. She is the dependent wife of Phil Huntley, a former Marine, that was stationed on Main Side. They lived in Tarawa Terrace.

And Phil has central nervous system vasculitis. He suffers just multiple strokes. He cannot live at home anymore. He is in the Iowa Veterans Home. He needs constant, round-the-clock care. And Terri has become very active in this situation. She’s sought out her senators and both of them have come onboard with the situation and co-signed, co-sponsored bills. And she’s gotten some media coverage out in Iowa, believe it or not.

**MR. STALLARD:** Will she be taking Denita’s vacant spot?

**MR. ENSMINGER:** Yes.
MR. STALLARD: So do we need to take a vote?
MR. ENSMINGER: Yes.
MR. BYRON: I’ll second the motion.
MR. PARTAIN: I’ll third it.
MR. STALLARD: All in favor?

(Whereupon members voted in favor.)
MR. STALLARD: Any opposed?
MR. PARTAIN: We didn’t hear from the people on the phone.
MS. BRIDGES (by Telephone): Sandy Bridges, I’m in favor.
MR. STALLARD: Thank you, Sandy.

Allen? Tom?
MR. TOWNSEND (by Telephone): I’m in favor.
MR. MENARD (by Telephone): Yes, I’m in favor.
MR. STALLARD: Okay, very good. Thank you.

There’s a couple things before we move on. I’d like to hear from Dr. Clapp. He had something to say about the CAPs, and I think that from what we’ve heard from the community side is about the representation.

We also have government representatives on this
CAP, and the question I have to ask is are they the appropriate people and the appropriate representatives of their agencies? We still would like to have somebody from the Veterans Administration. I think that’s outstanding to be addressed, and hopefully this afternoon maybe we’ll get some clarity on that. And so I’m just throwing that out there. It’s not just the community. We’re all part of this panel. Okay.

**DR. CLAPP:** Just going back to the structure again and a question came up about I guess you’d say professional epidemiologists or trained epidemiologists on the CAP. And I’m the only one right now. I think I’d describe myself as the last epidemiologist standing in this effort. And it reminded me --

**MR. PARTAIN:** Dr. Davis is.

**DR. CLAPP:** Dr. Davis, right.

**MR. PARTAIN:** She’s ill.

**DR. CLAPP:** I stand corrected. Dr. Devra Davis, who is an epidemiologist, is going to join or has joined. The previous experience that I had on this
-- this is really a narrow point, but it’s about the
structure. It was with the Otis Air Force Base–Camp
Edwards study. This is the upper Cape Cod study
around another military base.

It’s a superfund site in which the study was
actually done, the initial study was done by
colleagues at BU School of Public Health, David
Ozonoff and Ann Aschengrau were the co-principal
investigators of this in the early 1990s. And there
was a community advisory committee that was chaired
by actually a professor of mathematics at the local
community college on Cape Cod.

It had several other members who were actually
on the advisory committee to the study because they
had been part of a base transition team as it was
being transferred from the federal military to the
state air national guard and the state army. I
guess national guard. And that led them to want to
know what were the impacts of the pollution from
that site, and it had a lot of similar
characteristics to this committee.

But there was a separate professional advisory
committee which I was on and Dr. Steve Lagakos and Dr. Richard Monson, the three of us were the professional advisory committee. We sometimes met together, but often we met separately. And the veterans, well, not the veterans, the community members were pushing the researchers to do more study of the type of exposure that people got from the base and how it was modeled and so forth, very sophisticated input actually, the math professor in particular.

And the researchers, Dr. Ozonoff and Aschengrau, came to us, the professionals, to say what about this. And I remember saying or I remember Dr. Monson saying -- this is really a small point -- but the way that the math professor had proposed modeling it was probably inappropriate for the type of exposure it was, but the researchers went ahead and did it anyway.

And it actually didn’t wind up saying anything different than the way they had originally planned to monitor it, but it was an example where the professionals actually disagreed, or at least one of
the professionals actually disagreed, with the community advisory board.

And the upshot was the researchers did what the community recommended anyway. And I guess the point of saying all that is that you can either have the professionals separate or as part of the CAP, and I recommend as part of the CAP. I think that the process is better that way. And the outcome might be better or it might not make a difference, but at least there’s more communication.

MR. STALLARD: Thank you.

Frank, do you want to wind up?

DR. BOVE: That CAP had some difficulties and there was a lot of animosity between the community members and the state and the military and even with ATSDR. It was a situation where things had broken down so much that the state was trying to get out of doing anything more. We were trying to get out from doing anything more. Some of the researchers high-tailed it out because of the clashes. And I got involved at that point because I wanted the state to stay in. I wanted us to stay in. I wanted the state to stay
in.

MR. ENSMINGER: in all of them.

DR. BOVE: I wanted us to stay in, and I wanted to find some solution, and it was very difficult. But what we did is, and later -- I don’t know the chronology --

DR. CLAPP: But this was later. What you’re talking about was later than what I was talking about.

DR. BOVE: Yeah, was to ask the three CAP members, because at that point there were only three CAP members, a very closely knit group of people who’d been active on this issue going back to issues on the Cape in the ‘60s and ‘70s, ‘70s at least.

And we said to them, okay, we need to have this CAP continue. We want this research to continue. Let’s all of us agree on some researchers that we can all agree on and have them develop a plan. And that actually worked, happened, and a plan was developed and some more studies were done with that.

So I think that Dick’s right. That it’s good to have the professionals in with the community people and hash it out. I think that that works
better than separate. But I’ve seen it done both ways. I think in the Mattel-Tyco situation a group of scientists had conference calls with the state, and then there was a community thing, not a CAP, separate.

So each site in each situation they developed a different mechanism and some worked. Sometimes it’s just meetings with the affected families. At Brick Township, NJ [i.e., the ATSDR/CDC autism cluster investigation], for example, meeting with family in their home with a few other families and hashing out with their expert what to do. That worked pretty well.

So sometimes these things don’t work. At Fallon with the childhood leukemia cluster there, things didn’t gel as well I think, but it really depends. And again, whether it’s representative or whether it’s made up of key people, there’s no guarantee of success either way. It really depends on the situation and what seems to work.

And what we want, what the Agency wants I think -- sometimes I’m not sure what the Agency wants --
well, actually, what the Agency should want is input
that can help us direct our work. It’s my firm
belief that community input improves the science.
I’ve seen it done at Woburn. I’ve seen it at Brick
Township, not so much at Fallon.

But I’ve seen the science improve when the
community is involved at the ground floor and helps
the researchers see things that they wouldn’t see
otherwise because they do not live in that community
and do not know all the details of what’s going on.

And it’s certainly the case with Camp Lejeune.
We’ve learned a hell of a lot from the community
people, and we’re still learning today. So I think
that that’s the purpose of the CAP is to actually
educate us as professionals in the Agency as to what
the hell’s going on at the base, what has happened
and give us some direction.

MR. STALLARD: Thank you.

MR. ENSMINGER: Chris had a good point. This is
Jerry Ensminger. Chris brought up a good point
about the DOD representatives. Why isn’t there
somebody on this CAP from Headquarters Marine Corps’
Installations and Logistics Management? I mean, they’re supposed to be the experts in this, the controlling force. They handle environmental issues for the Marine Corps at all Marine Corps bases, and they don’t have a representative on here.

Now, I mean, we don’t need a messenger. Somebody who’s going to sit here and say I don’t know. I’ll get back to you and take notes and run back to their Headquarters and then have all their attorneys go over all this with questions and then their responses and before we get anything out of them. I mean, if you just can’t sit here and answer the questions honestly, what the hell are they here for?

**MR. BYRON:** This is Jeff Byron. And just as an example, I mean, and I haven’t heard this presentation yet, but we have a handout here. It’s DOD Birth and Infant Health Registry. Well, how long has this been going on? How many years has that been in effect? Nobody’s told the Camp Lejeune victims that there’s a Birth and Infant Health Registry? We’ve only been here for four years.
MS. SIMMONS: Since ‘98.

MR. STALLARD: Nineteen ninety-eight.

MR. BYRON: Since 1998. Now, we need to get back to honesty, transparency and back to really the business at hand instead of discussing our structure. I thought our structure was fine personally. It appeared to me that we were moving along.

MR. ENSMINGER: Is this grandfathered?

MR. BYRON: Hang on.

It appeared to me that we were moving along with mortality and cancer incidence studies, but these roadblocks keep popping up. One is funding. We’re not getting any from DOD. How is the water modeling going at Camp Lejeune on Main Side? That’s what I really want to hear about.

When will the in utero study be done? And I don’t want to hear, you know, this year that it’s going to be 2013 now. How about we have transparency and get the information that we need. And when we ask for a member onto the CAP, that it’s not just shuffled off to the side because the VA
representation, this is the third meeting since we asked them to be involved. And I’ve asked them to be involved since 2002, by the way.

So transparency, honesty, handing over the rest of the documentation of COWs, which how many of those is the DOD still holding based on national security interests? That’s what I’d like to know. Because there’s not one single document that should be held back from the victims at this point unless you can show my senator the documents, and he can tell me personally that there are national security interests involved here.

Because he’s about the only person I’m going to believe that looks at those documents unless I get them myself. And then I think I can determine, but that’s the real question here.

MR. STALLARD: Thank you, Jeff.

So it would appear that as a CAP unless we can, unless someone steps forward to present what is not working with this group that needs to be addressed and fixed and implemented, my sense is that this is a pretty good model of an effective CAP from the
members who have spoken thus far.

MR. BYRON: This is Jeff.

Frank, is this an effective CAP or is it not?

DR. BOVE: I said so.

MR. BYRON: We follow parliamentary procedure, and we make the nominations or some member makes a nomination to bring on a new CAP member. It’s seconded. It’s voted on plain and simple. If you’re not in the CAP you can’t make a nomination unless you want to present it to a CAP member for someone to be presented at a meeting.

MR. STALLARD: I can imagine that based on the media coverage there’s going to be a lot more interest and focus. And I know that Jerry probably has more people who want to participate, who want to be here. And so there needs to be some structure and process to that, but it seems like --

DR. BOVE: Well, one of the things again that I forgot to mention that’s been raised is when we nominate a new CAP member, when someone nominates a new CAP member, I think what would be useful is to find out exactly what that CAP member can provide or
what kind of work the CAP member wants to do that
would complement what’s being done already.

So I think that that is one thing I’ve heard
over and over again. And I don’t think that’s a bad
idea actually. It’s one of the few ones I’ve heard
that I didn’t think was bad. So if we can do that,
that might be helpful. We’ll nominate this person.
This person has acted, can do this, that and the
other that we think is important for the CAP’s work
and for ATSDR’s work.

MR. BYRON: And I agree with that. This is Jeff.
And I think we also need to get a verbal commitment
that they will try to be at the meeting. I know we
have some individuals that can’t make it, like Tom
because he’s older and has some issues walking, but
we need to try to be here face to face and
interacting eye to eye. And I think that’s very
critical.

So whoever we nominate in the future needs to
make that commitment that they are going to be here
just about no matter what. I’ve not missed a single
one. Jerry’s not missed a single one. It’d almost
have to be a death in the family to do that.

**MS. RUCKART:** Well, I have a question. So you have a request to nominate this new person and everybody accepted that. But you said something like she’s filling Denita’s seat. So seven, are we right now saying that we feel that seven is our maximum? Because there’s this discussion, Frank said if you want to add somebody what strengths do they bring to the table that’s not already present here.

And I think that make sense because you all are supposed to be representing the groups. And we talked about how you’re doing that except for maybe there’s someone not representing civilian employees, but otherwise we feel that we’re covered with all the different groups that were on base.

So I was just curious. Are we saying that we think seven’s a good number, and we’ll nominate as needed to replace or are we saying we think nominations should be open regardless of the number?

**MR. ENSMINGER:** No. We started with seven. Seven is, in my opinion, the working number that we will work with and the two experts. I mean, we’re not
asking for any increases. And Terri Huntley represents a dependent wife of a Marine who had a good job, had good health insurance, because of his strokes lost his job, lost his health insurance.

He’s in a veterans’ home now, but he does not have veterans’ benefits. They’re having to pay and scrape and scrimp, and it’s had a heck of an impact on these people’s lives. And from that aspect and that point of view she would be very useful on this CAP for the struggles that these people are going through that she could represent them and voice that at these meetings and that is important.

MR. STALLARD: Thank you.

Let’s wrap this up real quick.

MR. PARTAIN: Yeah, one thing, with Terri she’s also a mother of a child who was born at Camp Lejeune and a child who was several months old when they arrived at Tarawa Terrace. So she represents the entire spectrum in the community as well.

Now, one thing, too, as a member of the CAP we also represent the community. We do need to hear from the community and not just wild speculation or
things but constructive, documented input. So things that the community can bring to us that we can bring to the table, going back to the example of the interconnection between Hadnot Point and Holcomb Boulevard.

There are people out there that have documentation or expertise that can be brought up to us so we can bring things up like that. The CAP is not here asking for compensation or, you know, that’s not our purpose. But the community can get involved through us by helping us bring the history bringing out the exposures and everything, and we ask that and communicate that to us.

**DR. BOVE:** And one of the things you could also do is give us a sense of what kinds of things you’re getting from your website. What kinds of concerns, what kinds of issues are they raising. If you could bring that up each CAP meeting, I think that that’s another thing that I’ve heard people ask why don’t the CAP members tell us what’s going on with their website, what kind of concerns people have, and I think that’s a good idea, too.
So if we can do that from now on, I’d really appreciate it, and in between, too, if there are issues that are being raised. You hear stuff. For example, about male breast cancer increase from the ones you’ve identified 20 now to 49. That’s interesting to know. We didn’t know how many, or I didn’t, we don’t trust CNN as our source necessarily. We’d like to hear from what you have to say.

Now, there have been a couple of recommendations or suggestions. One is to have someone from Headquarters Marines on the CAP. Another is to have a VA rep on the CAP. I think that we should discuss this at some point during this meeting further or come to a consensus on whether we want to ask, we want ATSDR to ask or who asks these people to be on the CAP.

**MR. STALLARD:** Mary Ann, you had something?

**MS. SIMMONS:** Yeah, I just had a quick, I’m just trying to get this clear in my own mind. So would everybody agree that a mission statement could be for the CAP, for the purpose is how ATSDR should do
future studies and help communicate about future studies?

**MS. RUCKART:** As well as the ongoing studies?

**DR. BOVE:** Well, also to be the eyes and ears of the community, to let us know what kinds of concerns are coming in. For example, is the CDC info providing proper responses to people. We’ve heard problems in the past. That’s been very helpful trying to correct them. Other issues that might arise that you find out that you could let us know then that would be important.

**MR. ENSMINGER:** Eyes, ears and voice.

**MR. STALLARD:** Let me interject here because we could take absolutely all day trying to come up with a mission statement. But I appreciate that Mary Ann’s taking a stab at it. And what I would suggest is for the next meeting we perhaps have a draft mission statement that would be a step toward structure, if you will, that we can publish and say this is what we’re all about that’s all encompassing of what we’ve talked about here today. Is that fair to say? Let’s set some time aside to do that at the
next meeting?

MR. ENSMINGER: I notice on our agenda there's nothing on here about the funding for FY2010.

MS. RUCKART: Yes, it's there.

MR. ENSMINGER: Where?

MS. RUCKART: Future studies.

MR. STALLARD: Right. And what I'd like to do is before we convene, finish for today, I would like to talk about the representation. We're going to have a presentation from the VA. It might be useful, depending upon how that goes and the position of the presenter in the organization, how best to go about doing that.

MR. ENSMINGER: Is the VA going to be a permanent member of this CAP?

MR. STALLARD: I'm not in a position to answer that. We can ask that during the presentation or shortly thereafter who to talk to.

Did you have something you wanted to say?

DR. CLAPP: Yeah, it was really about, one more thing about a successful CAP is to have a good facilitator. And in my experience we've got an
outstanding facilitator standing here in front of us, and I just want to commend you for that.

MR. STALLARD: Thank you.

Well, with that we’re a half hour behind time.

MS. RUCKART: And we just want to give you kudos.

MR. PARTAIN: I want to just add before we go. This discussion of mission statements and purpose and things like that, I just want to make sure that this isn’t a discussion to put limitations, constraints on the CAP.

I mean, if we see an issue that needs to be addressed, and if there’s some type of mission statement that’s put out, and it’s outside that, we do not need to be constrained by that if it’s a valid and legitimate issue. And I just want to express that concern and that thing that’s been bouncing around in my head.

MR. ENSMINGER: No, we’re going to do a draft so that we can address all this stuff.

MR. STALLARD: We’re going to take a break and it’s going to be ten minutes. So please be back in ten minutes.
(Whereupon, a break was taken from 10:30 a.m. until 10:45 a.m.)

**MR. STALLARD:** I have a little administrivia for you. If you haven’t signed in, please do so. Who’s got the sign-in list? It’s going to make it’s way around the table and the audience. We’d like, we don’t just like to, we do keep track of who is here through the sign-in sheets.

I met with Tom Kniffen --

Did I pronounce that right?

**MR. KNIFFEN:** Yes, you did.

**MR. STALLARD:** -- who is here from the Veterans Administration and the Under Secretary’s Office. He’ll give you the whole organizational role that he plays there. But after lunch I’m going to invite Tom to come sit here and his presentation I think based on his experience this morning, he wants to tailor a little bit and have an open sort of more informal dialogue with you all. So we’re going to work with him and invite him to the table shortly after lunch.

**WATER MODELING UPDATE**
Welcome back for another exciting installment of Morris Maslia’s presentation on the water modeling.

MR. MASLIA: We’re ready to begin. I’m going to give you an update on some databases and modeling activities that we’ve done and not a very long presentation then open it up to specific questions.

I have placed three posters around and I’ll explain what they are in just a minute. They are in draft form, and if those are not located strategically, please feel free to move it. I do have it up on the screen, but the resolution on the screen up here is not the resolution of a poster.

Before I get to the posters, we had at the end of September, actually the end of August, the expert panel report with the verbatim transcript. We had the report and transcript reviewed internally, and then sent the documents to all stakeholders and members of the expert panel, and courtesy copies were sent as well to some of the Agency’s external contacts. The purpose was to verify and check the verbatim transcripts because there were a lot of
technical jargon that needed to be looked at as well as to see if we interpreted or misinterpreted any salient points.

We have gotten back responses from a number of experts on the panel, which is really what I was concerned with for the expert panel report. Again, the expert panel report is not necessarily an interpretive report but just an attempt to capture what went on in the meeting and what the recommendations were for the benefit of the stakeholders, the CAP, Department of Navy, Marine Corps and so on.

At the same time, or nearly at the same time which was a challenge, we also sent out for what we were calling data verification and review, what we’re referring to as the Chapter C report of the Hadnot Point-Holcomb Boulevard data. This is the data report on strictly the IRP sites.

As you know last March we were provided with additional information or data which we are referring to as the underground storage/above ground storage tank, ASD-USD sites. And because of the
number of reports, I don’t know at this time, but
the number of reports, we decided to separate out
the data into Installation Restoration Program sites
and underground storage. That’s why there’ll be two
separate data-type reports.

We’re still going through the UST-type reports
as I speak, but the Chapter C report, again, we sent
out for people to look at, the data, if there are
any questions that arise. I will tell you that is
not an interpretive report. There is no simulation
involved in it. I think the last couple pages in
the summary we made some interpretation as far as
the quality of data, where it came from, why some of
it’s better than other data. But in terms of where
the groundwater flows and things like the water
contaminants originated from, we don’t do that in
that report. That’s not the purpose of the report.

The purpose primarily is because there was
orders of magnitude more data at Hadnot Point than
at Tarawa Terrace. Rather than repeating all the
data and all the modeling reports subsequent to that
or piece-mealing the data, we felt it would be
better to put all these documents from the disparate sources that we obtained into one report so everyone would sort of be on the same page.

So if one was referring to a certain well and certain concentration, they could refer to that report and we would all be there. So the plan is to get comments back, revise the reports accordingly, and hopefully, before the end of this calendar year have them published and on our website. That’s the plan.

We were provided about 10,000 records of water distribution system operations data from the Marine Corps from the water utilities on site from like ’98 to 2008. They scanned those in, and we did have temporary workers, and we provided them with input templates, and all of that has been entered, not necessarily quality checked, but it has been entered. And so that’s where that activity is at...

We will, as we did with the IRP site data I’m going to show you in a minute, the UST site data we will also need to input that data and have workers as well enter that information.
That brings us to what I wanted to show you some of the effort that this chart here basically is a consequence of about 18-to-24 months worth of effort. And what it shows really we have I think for the first time captured all supply wells that we know about and been provided information in some logical and chronological order.

And what this shows -- and I’ll point it out here -- for example, here’s HP-601, the open circle says when it began operations. The solid line is when it’s operating. The solid blue line is when it finished operating or taken offline, and the red ones -- if you’re color blind, I’m sorry, but it’s got some letters -- that is documented contamination. The chart is not a modeling chart. This is strictly data information that we retrieved by going through the documents, either CLW documents, CERCLA files and so on.

The reason we need this information, number one, is, for example, when modeling a particular well’s operation. For example, modeling well HP-605. I think that’s HP-605; I’ll move my mouse here. HP-
605. And you say, well, gee, it stopped. It’s not even getting into hardly the period of the study, but that’s not true because you’ve got another well in its identical location picking up from there. So now we know we have pumping all the way through here, but it’s just changed the well out.

This is the first step in how you’re going to organize the data on well operation for modeling - you need to recognize the chronology of the well operations. And we have separated this out by service area. This would be the Hadnot Point area, and again, the lighter green below is the Holcomb Boulevard area.

Now, what we’ve done, this is nice and helpful for us, but the more powerful aspect of this is, for example, if you wanted to look at Well-601, we can link it. And now this pulls up all the information and the chronology that we have retrieved from documents provided from various sources, the capacities where we have them, and the data source. In other words whether it’s a driller source, a capacity draw-down test. Down here the documents
where the referencing material where we obtained it from. And if we go right here we also note, for example, that Well-601 was replaced by Well-660.

So all this is behind that, and if we go one further step we can do the same thing. And, for example, right here if we click on Well-653, we now pull up -- and I don’t know why that one’s not coming up, but we’ll, there you go. We now see behind that we can see the concentrations PCE, TCE and so on. Or if we go to one that’s with an example of benzene, recorded benzene, you can see that.

So the natural extension of this would be then at some point this can be provided as an information source for the public by just putting something like this up on your website, and you can click on the different wells and see the background material, when it operated, what the contamination levels were. Again, this is from the documents. There’s no modeling involved on here. It’s just strictly from the documents that we have been provided by the Navy and Marine Corps.
And so that is what we have. The entire staff basically has been spending the last 18 months going through the various documents trying to resolve any conflicts, reviewing the conversations we’ve had with the water utility guys at Camp Lejeune trying to figure out when certain wells were operating, because all this is important information to assemble before we ever start the first modeling activity.

So is there any question on this aspect? Actually, let me finish because I’ve just got a little more to go.

So that brings us to the actual modeling issue or historical reconstructing of concentrations. And in our expert panel as well as the NRC report the recommendation was made to use -- I’m putting it in quotations -- simpler modeling. And that’s a nice term and unfortunately it really does us a disservice because it doesn’t tell us what simpler means.

And our concern is that what we may think is simpler may not be considered simpler by our
critics, not that we shouldn’t get critiqued, but our critics may say that that’s not the direction we wanted you to go in, that it is too complex or too simple. As an example, we were criticized because some people thought we made a too-simplified assumption at Tarawa Terrace.

So what we are in the process of doing, I’ve actually got a draft and hopefully it’ll go through internal review within the next few weeks, is coming up with an ATSDR position paper on what, and I’m calling it Cost and Time Effective Methods for Modeling Hadnot Point and Holcomb Boulevard.

I’m trying to get away from the use of the word simpler because what’s simple to one person may be too simple or too complex to another person. And I think it clouds the issue. It’s trying to get, as someone said here, you know, not spending another five years doing something if we can get 60 percent assurance with some simpler approach in two years, why spend five years and only get 70 percent assurances. I mean, there’s going to be uncertainties in whatever we do. So that’s really
what we need to do.

And I think learning from Tarawa Terrace we need to have this position up front. So I brought an example. For example, one of the activities in this approach is to concentrate much more on data analyses. That was one of the recommendations of our expert panel. So for example, even though we may have limited observation data in terms of mass and time, we can still make some simplifying assumptions and come out with some trend lines here and even some spatial analyses -- this is conceptual -- whereby then we can determine if these simplifying assumptions can be used to model. That’s part of this position paper, using some parametric and non-parametric techniques.

Another thing that I want to point out is as part of this -- and you can’t see this -- but there’s really three, I would call them categories that we need to look at in order to come to terms with limiting the time and the cost associated with completing the model.

And the first one is the source
characterization, of course, because at Hadnot Point
unlike at Tarawa Terrace we do have D-NAPL, a Dense
Non-Aqueous Phase Liquid. So the question, the
comment is, yes, there are D-NAPL models out there,
but can we make some simplifying assumptions and
assume it’s dissolved.

Or can we assume if we’re doing a D-NAPL that
it’s stationary and the heavy, dense stuff is not
moving along in time. These are some of the things
that will be in the position paper. And the reason
that’s important is because there’s uncertainty
associated with all of this.

Obviously, the most rigorous approach would be
to assume a mobile D-NAPL source where we throw some
high-end, numerical code at it that would minimize
your uncertainty relatively speaking, but it would
increase your cost substantially both in time and in
money.

Another thing is, how are you going to classify
the aquifer? Should we model all 14 layers or can
we reduce it down to two or three, the pumping zone,
the source zone above and the source zone below and
get the likely concentrations that we need.

And in terms of simulation, you know, again, do we go with a multi-phase, stationary D-NAPL source or do we go with, which was shown at the expert panel, a control theory where we don’t care about the individual movement of the individual contaminant or water droplet in the aquifer itself, but what we’re more concerned about is what is the resulting concentration in the supply well every month.

So that’s what we have written in the draft position paper - a broad, general scheme. Frank will be reviewing it and it will be reviewed internally. And then once the Agency approves of it, what we intend to do is as our expert panel suggested bring two or three experts together and let them say yes or no or you missed this or you didn’t miss that. And hopefully within the next couple months that will take place, and then we will post that as our approach to doing the modeling.

The bottom line is simpler modeling can go all the way from taking that whatever it is, 18,000
parts per billion of TCE and assume everyone was
exposed to that supply well at one end. That’s a
simple model approach. All the way to the mobile,
non-stationary D-NAPL source at the other end. And
obviously what we want to do is try to minimize our
uncertainty and at the same time we want to minimize
our cost and time.

In terms of time we are targeting right now to
be completely finished by September of 2011. We
should have some preliminary results for the epi
people sometime in the latter part of 2010. That
really is -- oh, one last thing and then I’ll open
up for questions.

Next week, also I think it’s one of the
recommendations of our expert panel, we are bringing
in Dr. John Doherty, who’s a world renowned expert
in data analysis and parameter estimation.
Specifically, he is providing us some input and
interpretations with respect to the Hadnot Point
area, hopefully will guide us with his input as to
how we should approach data analyses. And he’ll be
here for three days. He’ll be presenting a lecture
over at Georgia Tech, lecture here not just for our
water modeling group but some other interested
people. And I believe that will be very useful and
helpful to us.

So with that I’ll open it up for questions.

Jerry.

MR. ENSMINGER: What’s the status of the expert
panel report?

MR. MASLIA: The status is we have gotten returned
reports. I asked for people to either mark on the
hard copies or send us an attachment with any
changes both in terms of the verbatim transcripts as
well as any other thoughts they may have. We got
them back from all I think but two of the expert
panel members.

I know you told me you would be providing it
this week or today.

And we still need to get comments back if they
have any or even if they don’t have any I’ve asked
people to send a report back and write on it you
don’t have any comments. All this is FOIA-able from
the Department of Navy/U.S. Marine Corps. We got
comments back from EPA as well as the CAP member as well ^ other stakeholders. So we’re waiting for a couple more returned reports.

Our contractor, Liz Burleson, with ERG is I’m pleased to say is back from family leave, and in fact, I’m meeting with her tomorrow to start resolving some of those comments. Most of the comments we’ve received are editorial-type. We can slide a week or two, but I really do not want to go past October of not getting responses back. Then we will have to make a decision to go with what we have.

MR. TOWNSEND (by Telephone): Morris?

MR. MASLIA: Yes.

MR. TOWNSEND (by Telephone): This is Tom. You explained that there’s a spectrum of difficulties or complexities ranging from increasing, incredibly complex to progressively very simplified. I just hope that any inference by the Defense Department of their desire not to pay is not influencing the down-grading of your studies to an acceptable level.

MR. MORRIS: No, actually, we submitted back in the
end of August I think, Frank, it was, our budget for FY10 and projected for FY11. And it really, in the Hadnot Point area I would say if you want to call it difficulty or what takes up the time and money is the data analysis. That’s really where the crunch is unlike at Tarawa Terrace where we had only 12 wells, really only, at one time, three or four operating. So trial and error to get the model to run was sufficient.

Here, as you see by the chart, there, even just during the epi period from ’68 through ’85, you’ve got about 30-some-odd wells. And as I said, just to get that chart took us about 18 months to put together to get some logical and rational approach that we can all refer to a common base to put in there.

So that’s really, if you go to a simpler model, it runs faster, but you may have to make more analyses because you have some limitations you need to test out. That’s one of the reasons we’re bringing in somebody like John Doherty, who’s an expert in some of these techniques that we can use.
So the answer is no. We submitted a budget sufficient for us to be able to provide monthly concentrations at Hadnot Point for the epi study. That’s really the driving force behind our budget considerations.

MR. ENSMINGER: Morris, what about Chapter C, the data report?

MR. MASLIA: Chapter C, we asked for it to be back October 16th, which is, I think, the end of next week, the end of this week. My phone message still says it’s September, so... And it is, again, we sent it out to what I’m referring the stakeholders, Navy and Marine Corps. We also sent it out to the North Carolina DNR. They wrote back that they just want to be kept in the loop, but they had no comments.

We also sent it out to the North Carolina Water Science Center from USGS because they’re doing on-base studies as well. They reviewed it and said, again, just keep us in the loop, but we have no critique of the report, which is fine. Those who are more keenly interested or more familiar with the
information, we would hope that they would go through at least some of the tables.

I can assure you our staff has been using both temp work, temporary workers, as well as, as I said, going through all of the tables and all of the references. And as you know with any report of that magnitude no matter how many times you go through it, accuracy is our goal. And again, my aim is to get that published before the end of the calendar year.

And one of the things I might add, that we learned from the expert panel was having as much of the data in printed form. Because in the expert panel, if you’ll recall, we provided some printed sample tables and then we put the rest of it on a CD for them to look at. The feedback we got was that the panel members could not find this table or that table, and that convinced us that we should not just provide a few printed sample tables and then refer them to a CD.

So as a consequence, we’re planning to print out all 80 tables in the report and all 30-some-odd
figures and stuff like that. We’ll still provide the CD for look-up and stuff like that, but our conclusion was that if a room full of experts had trouble doing that, that would not be a good way to present the information to the public, just have them referred to a CD, so it will be printed out.

So that’s our goal. Our goal is to get both the expert panel report and the Chapter C report, the IRP site data report online and printed by the end of the calendar year. And I’ll just say on the Chapter C it will be vitally important to get some feedback from those people that we have sent the report to.

Any other questions?

CAPTIONER (by Telephone): I have a question from a ^.

MR. MASLIA: Somebody’s got a question but I can’t hear it.

MS. RUCKART: Is that the closed captioner?

CAPTIONER (by Telephone): Yes, ma’am.

MS. RUCKART: We’re not taking any questions.

Please tell that person to submit the question
through ATSDR’s Camp Lejeune e-mail, CDCinfo, or to, well, I guess it’s a question for us on water modeling? Yeah, so they wouldn’t go to the community. Just have them send it to us.

CAPTIONER (by Telephone): Okay.

MR. STALLARD: Did we have a change in the closed captioner? Okay.

MR. PARTAIN: Morris, you’ve got on this chart here Holcomb Boulevard Well-706.

MR. MASLIA: Right.

MR. PARTAIN: It’s showing contamination with benzene. What’s the story behind that? I’m not aware of this well.

MR. MASLIA: Well-706?

MR. PARTAIN: Yeah. It’s on the bottom of the chart.

MR. MASLIA: Hold on. First of all, let’s see when it operated. That came in in 1986, and that’s in 2001 it was noted as contaminated. And then in 2001, and let me tell you what the levels in that were --

MR. PARTAIN: Do we know what the levels were?
MR. MASLIA: Yes, yes, let me get that right now, 0.6 micrograms per liter, and then in ‘98 it had 6.1. That’s probably, you know, a spill from one of the above ground or underground storage tank areas where it had a local impact.

MR. PARTAIN: Yeah, it looks like it’s across the street from the Piney Green Shopping Center. It looks like there’s a gas station not too far from there.

MR. STALLARD: Anything else for Morris?

MR. MASLIA: We’ll also have like we did with the capacity, the referencing information on these sheets. We just didn’t get a chance to put them on for this presentation, but that will be on here.

Any other questions?

MS. SIMMONS: Is this information available on your website?

MR. MASLIA: This is in draft. It says draft on it. This is the type of information that I feel that once it’s approved, when Chapter C is approved, this will be on our website because all the data tables behind this chart are in Chapter C. So this
information is nothing different than is presented in Chapter C. It’s just presented in a compact form.

And this is a web application, for example, that I could see putting on our website that involves no simulation, no interpretation. But rather than going through all the CLW files and stuff like that, someone could just look at that, click on the well and get that.

**MS. SIMMONS:** I think this is really useful.

**MR. MASLIA:** Thank you. Thank you.

**MR. STALLARD:** And this is like a simplified reduction of everything?

**MR. MASLIA:** Yes, that is, and that’s sort of unique in that it puts everything, all the documents and the different types of documents and all of that, it still provides you with a source that came from a CLW file. That was already, the CLW files, are up on a CD or on the website.

Somebody can go and read through them. We had to go through them to decipher sometimes what numbers to use and stuff like that. But, yeah, this
presents the entire chronology and listing of wells from 1941 through 2008 for the Hadnot Point-Holcomb Boulevard area.

**MR. STALLARD:** Maybe I missed it, so when might that be available?

**MR. MASLIA:** Once Chapter C is approved, and when I say approved, comes back from the external review and cleared by ATSDR, then we would get with our web people and --

**DR. BOVE:** Next year?

**MR. MASLIA:** -- I’d say probably beginning of next calendar year to do that.

**MR. STALLARD:** Thank you, Morris.

Any other questions?

(no response)

**MR. STALLARD:** Thank you very much.

**RECAP OF LAST MEETING**

Okay, we’re going to move on now and have Perri give us a brief update from what transpired since the last meeting of July 8th.

**MS. RUCKART:** Well, I’ve passed out this handout. It’s just a summary of our last meeting. At our
last meeting we had a presentation from Christian Scheel on the new ATSDR Camp Lejeune website. And he mentioned that we would be requesting the CAP and the community’s assistance to further improve the website.

And I sent you an e-mail on September 10th asking for volunteers to participate in what is called a card sorting study. We had a few people volunteer for that. I think the deadline is right around now, so I’m not sure if it’s passed or it’s coming up. But anyway, that’s coming to an end. So I guess there will be some more refinements to the website after he looks at the feedback.

At the last meeting there was a request for ATSDR to provide a copy of the letter sent to the VA in which we requested a representative for that July CAP meeting. And we e-mailed that to you right after the meeting that same day, July 8th.

We had a lot of discussion at the last meeting about the need to engage the VA to be present at the meeting. You can see some actions that we took, but the end result is we do have somebody here today
who’ll be giving a presentation in the afternoon.

At the last meeting Bill Cibulus said he would look into how the PHA came up with 3 parts per billion vinyl chloride.

You were going to say something about that?

DR. BOVE: That’s an estimate from the lab. The vinyl chloride level was below the detection limit, and so that’s just an estimate that the lab makes. You know, we don’t make an estimate.

MR. ENSMINGER: Who sets the detection limit?

DR. BOVE: The method itself has a detection limit, and I would say the vinyl chloride -- well, I don’t know. I’d have to look up the detection limit. It could be as high as 100 parts per billion. I don’t know what the detection limit is.

MS. RUCKART: Also discussed at the last meeting, a request for ATSDR to submit a list of questions to EPA as to whether or not the LOAEL was properly used in the NRC report, and I guess, the Agency did not do that.

DR. BOVE: Well, I mean, to be transparent we had internal discussions about this issue, but nothing
formal was done. So why? I don’t know why. Not because of interest on our part. I think that the decision -- I’m not sure how the decision was made and who made the decision. But the decision was made to focus on the epi and the water modeling aspects of the NRC report and not to deal with the tox issues.

We went back and forth because earlier drafts had some statements about how we felt about the use of the LOAEL in the NRC report, and the NRC report’s conclusions on TCE in comparison to previous NRC reports on TCE, for example. But then that material disappeared from the final draft, and I don’t know how that happened. I was not part of that discussion. So we did not do that.

There’ve been informal discussions, conversations between EPA and us, some of it around, of course, the TCE risk assessment that’s in draft as well. So those conversations have been ongoing but nothing formal between the two agencies has been written down.

What I said at the last meeting was what I
thought which was that the LOAEL was used inappropriately, and I reiterate that today. But that’s not an official ATSDR position.

**MS. RUCKART:** At the last meeting we discussed if the CAP would send ATSDR their written response on the NRC report, and earlier we talked about how that happened. We got the response on July 24th. Tom talked about this, too. He was talking about our updates, what we as an Agency have been doing since our last meeting.

And as he mentioned we issued a final plan for Camp Lejeune, and we did brief the CAP August 12th about that. That’s our response to the NRC report. And Tom discussed that he received comments from various agencies, NRDC and others, and we formulated a plan that’s also been posted on our website.

We can get into that a little bit later coming up when we talk about some of the items under future studies, and we can talk about specific items in our plan.

**DR. BOVE:** Actually, we never did brief the CAP on the actual response, did we? Because the CAP
meeting was in July. This came out in August.

**MS. RUCKART:** No, we had that conference call on August 12th.

**DR. BOVE:** Oh, that’s right.

**MS. RUCKART:** But we can get into some more specifics on what’s been going on since August 12th a little bit later this morning.

So at the last meeting there was a request for Mary Ann to find out if the military has a birth defects and cancer registry currently, and a mortality database for children born to active-duty Marines and when they started. I have passed out something that Mary Ann sent to me on the DOD Birth and Infant Health Registry.

Did you want to say something about that?

**MS. SIMMONS:** No, just that it started in 1998, and I think, Jerry, you asked if it was grandfathered. I assumed you mean retroactive, and it’s not. It just started in ’98. There is a cancer registry within the Navy or at least I know about the Navy.

However, what I was told that there’s issues with pediatric cases because if a child is
diagnosed, they usually send him to a specialist right away. So that information may not always be captured by the cancer registry.

**MS. RUCKART:** There was some discussion at the last meeting for Scott’s e-mail to ATSDR, the file he distributed at the meeting on notification and registration first by the USMC. And Scott told me he noticed the CAP was able to scan the handout with just the color contrast the number showed up, and he said he provided something additional since then.

And then Christopher passed out during the break some notification updates. You can see here their efforts at notifying people, the numbers they’ve reached and some information by state.

That’s all we have for the summary.

**MR. STALLARD:** Any points of clarification?

**MR. ENSMINGER:** The thing about the pediatric oncology or cancer cases, when Janie was diagnosed, her diagnosis was suspected at Camp Lejeune. And I had to take her to Norfolk to Portsmouth Naval Hospital to confirm her diagnosis, which was another military hospital. So I mean, aren’t all the
pediatric cancer cases diagnosed by the military, a
confirmed diagnosis?

**MS. SIMMONS:** What I was told is not necessarily. Like I work at Portsmouth, and what the person who was explaining this to me said if they would get a child in who they suspected might have leukemia, that they would send the child to King’s Daughters, which is a private hospital in Norfolk. So my understanding is they’re sending more pediatric cases to outside the military health system to be treated because they have the better specialties.

**MR. ENSMINGER:** Oh, yeah, but I understand that. But back when Janie was diagnosed, it was almost like she had to be diagnosed by the military facility back at that time. I mean that’s half dozen or the other. I mean, you know, these children when their diagnoses are confirmed whether it’s King’s Daughters or Duke University. I mean, the parents are going to have to come back and let the military know because that child’s healthcare is being provided through the military system. So for them not to capture that is a bunch
of crap. I mean, somebody’s blowing smoke here.

MR. STALLARD: So you want clarity? Is that correct? You want clarity on whether or not if they’re referred out --

MR. ENSMINGER: Yeah, I mean, there should be no child escaping the military’s cancer registries because the military’s ending up having to foot the bill for that child’s treatment no matter where it is.

MR. STALLARD: So ^ how is it entered into this registry, for instance, and captured.

MR. ENSMINGER: Well, that’s up to them.

MR. TOWNSEND (by Telephone): Chris?

MR. STALLARD: Yeah, go ahead, Tom.

MR. TOWNSEND (by Telephone): I have a comment on that although my child was not a cancer patient, but when I reported a problem with my child in ’67 at Camp Lejeune I was referred for pediatric advice to take the child to Bethesda. So at that time referrals for these exotic types of things went from ^ like Camp Lejeune, they went to Bethesda. There was a long time period that they did not go outside
the military chain.

**MR. STALLARD:** Thank you.

**DR. BOVE:** We looked into what’s called ACTUR.

**MS. SIMMONS:** ACTUR?

**DR. BOVE:** A-C-T-U-R, the DOD’s automated cancer tumor registry, and I’m trying to remember. From what I gathered when I did the feasibility assessment, when I did that work I looked at ACTUR. It is a so-called passive surveillance system. The completeness of reporting from DOD treatment facilities is unknown. It was established in mid-’86. I can go back and see if there’s more recent information about the registry in any scientific reports and get a handle on it.

We have, Perri and I have contacted ACTUR awhile ago now and asked for their help as well in verifying, confirming cases that come to us through the health survey. They’re willing to participate. I have a feeling that I don’t know how useful that database is. That’s why we want to use states to help us as well and the VA and so on. So we never want to rely on this database. Apparently, it’s not
clear how useful it is for research.

MS. RUCKART: Well, I’ll just add to that in
addition to VA databases and the state cancer
registries, we also have the support of the DOD
cancer registry. So all of the possible places --

DR. BOVE: The one I just talked about, ACTUR, is
the DOD one.

MS. RUCKART: Okay, and then we also have the VA.
So any possible place that these cancers could be
reported has pledged to cooperate with us. So we
have, you know, the best chance of actually
confirming any reported cancers.

MR. STALLARD: Okay, thanks.

FUTURE STUDIES

So we’re going to move in now to your future
studies update.

MR. BYRON: This is Jeff. I wanted to see if I
could get a copy of the introductory e-mail to the
new registrants. I’d like a copy of that if that’s
possible. I don’t remember getting that. This is
on the notification update. It’s on the last page
right before keeping contact information current.
MS. RUCKART: Yeah, Christopher Gamache indicated that he can provide that.

MR. BYRON: Will you get that today?

MR. GAMACHE: Not today but probably either by the end of this week.

MR. BYRON: No way I could get that today?

MR. GAMACHE: No.

MR. BYRON: You e-mailed it to people, can’t you e-mail it to us?

MR. GAMACHE: I don’t have my contractor’s phone number right now so it’ll be by the end of the week.

MR. BYRON: That don’t help me today. Okay, thanks.

DMDC DATA

DR. BOVE: We received a shipment of the DMDC data last week. I had a chance to just upload one file to see what shape it’s in. These are the active duty and civilian databases for Camp Pendleton and Camp Lejeune. It’s some 50 files. It’s done quarterly from ’75, except for ’75 there were only two quarters.

It started in June ’75. That’s when the data starts. So it’s quarterly after that to ’87. And
there are some issues about lining up the variables
that a contractor can certainly deal with quicker
than I can. So we have the data so far.

We may get another shipment of the data because
they may have left one important variable - the MCC,
the Military Command Code - off by mistake although
they have, in the data I saw they have a space for
it. And MCC was not coded in the database until
much later than '75. I can’t remember exactly when,
but at least in the late '70s, early '80s before
MCCs were in the database.

MR. ENSMINGER: What kind of identifiers were in
there earlier?

DR. BOVE: The RUC. They call it the UIC, but it’s
the RUC.

We got the civilian data a couple weeks ago,
and I actually loaded that in. That’s easier to
load in and did some frequencies on that, but I
don’t have them with me right this minute, but that
data’s ready, too. So I’d like to look at it a
little bit more, but I think we have what we wanted
from DMDC.
MS. RUCKART: Yeah, I want to add that it includes Camp Lejeune and Camp Pendleton. So we’re covered as far as our data needs to begin our studies when we’re able to do so.

FUNDING

I guess one part of being able to do so, I guess, is the funding. And as Morris mentioned earlier, we submitted our funding request late August. You know we work on a fiscal year so October 1st starts our fiscal year.

Carolyn Harris in a minute will come up to the table and give some more specifics on the funding, but we did get funding for this CAP meeting. We’ve not yet gotten the full funding, but we were pleased to get funding to at least travel everyone in and hold this meeting. We have funding for our salaries.

Would you like to come up now and give some more details about funding?

MR. ENSMINGER: What salaries?

MS. RUCKART: Well, Frank, myself, our internal salaries so that we can keep working on Camp Lejeune
MR. ENSMINGER: What about these temporary workers that Morris talks about that he’s got working? I mean, is he going to be able to continue --

DR. BOVE: That’s being worked out. That’s being worked out. From my last understanding -- there’s been a flurry of e-mails back and forth.

MS. HARRIS: Am I on?

MR. STALLARD: You’re on.

MS. HARRIS: My name is Carolyn Harris. I work with Perri and Frank. And I’m a public health analyst so I handle all the contracts and the funding for Camp Lejeune and have for the last 15 years.

He’s right. So far we don’t have approval yet from the military to fund Morris’ staff, but we’re hopeful that will come through soon.

MR. ENSMINGER: What are we talking here? I mean --

DR. BOVE: Well, for the temporary workers I think it was $50,000, and as I said, there was some back and forth within Morris’ division about this so I don’t have the latest on this. Maybe Morris can tell us later, trying to resolve that particular
issue. But as for the water modeling itself, Fiscal Year ‘10 and any future studies, we have not received funding yet.

MR. PARTAIN: Now, is this lack of funding disrupting, delaying, causing problems as far as y’all being unable to execute your job?

MS. RUCKART: Well, let’s let Carolyn give an update on where we are with funding and when we might expect some funding and then we can get into that.

MS. HARRIS: We have the mortality study ready to go as soon as we get the funding from the military. All the contractors have extended their quotes to January so that if we don’t get it in the first quarter, hopefully in January we can get some funding on the mortality study.

We have the health survey pilot and the health survey in the pipeline. We expect that it might be funded about the same time period in January.

MS. RUCKART: Can you tell us about that bill?

MS. HARRIS: Well, the Defense Reauthorization Bill, which has the appropriations, which leads to the funding is soon to be voted on in Congress. So, you
know, this happens every year with the funding cycle so usually when it’s approved, it doesn’t filter down to us until sometime between January and April so that we can actually get the contracts out the door.

**MS. RUCKART:** Now your questions about when we can actually start the studies, is it a funding issue or some other issues. Well, I’ll say that for the mortality study, it’s been approved by our IRB, Institutional Review Board, and it’s also received Agency and peer review approval.

Those are the only approvals we need for the mortality study. We don’t need to go to OMB because we’re not contacting anyone. The mortality study just links databases. So once we receive word that the funding has been received, and we select the contractor, we can begin meeting with them and actually start that study because now we have the DMDC data so we can hit the ground running.

As far as the health survey --

**DR. BOVE:** Hold on a second.

If, on the other hand, there’s -- and correct
me if I’m wrong -- if we don’t get funding soon, we may have to start the whole process over again to re-bid it and everything else.

MS. RUCKART: By January.

DR. BOVE: By the end of January we actually need to have a commitment.

MS. RUCKART: Yeah, but the Navy is aware of that fact.

So as far as the health survey this was mentioned in our final plans, and we can get into some more specific details in a few minutes how we’re going to be now moving in a slightly different direction and starting off with a pilot health survey. As far as that even if we were to get the funding tomorrow, let’s say, there’s still some extra hurdles.

We need to get OMB approval and recently, last month or I guess August now, a few weeks ago, we’ve had some interactions with OMB. And because we’re moving in this slightly new direction of including a pilot health survey, they had asked us to withdraw our submission for the full health survey, which we
MR. ENSMINGER: Who did?

MS. RUCKART: OMB asked us to formally withdraw our submission, our package, for the full health survey and re-submit to include the details of the pilot.

So we submitted here at CDC, I’m not sure if it’s left CDC and gone to OMB to be officially seen as our request for the -- Do you know, Anne?

MS. SOWELL: I do not know the status.

MS. RUCKART: So we here in the Agency have submitted that to our CDC OMB office, and we’re not sure if it left CDC. But anyway that’s inevitable.

So we are re-submitting a new OMB package, which includes the health survey pilot, internally here to our CDC OMB, and then it will leave and go to Washington OMB.

This is Anne Sowell. She can maybe answer more specific questions you have about the process.

But anyway, so the package has been revised just to include the pilot details.

Do you want me to talk about what’s going to happen as far as --
MR. ENSMINGER: Stop. Stop. Why did OMB come back and ask you to withdraw your initial proposal?

MS. SOWELL: They apparently have timelines they have to work on it because they delayed this review because they were waiting for the NRC report. They are way past their timeline. They have assured us that they will do an expedited review.

And, in fact, we have received assurances that when we re-submit it to OMB, we don’t have to do the 60-day notice and the 30-day notice. So that’s shortened the review process significantly.

And they, OMB Washington will have reviewed the package by the time it gets there so it should be a very simple thing. We don’t think this is going to add more than a couple of weeks to the timeline if we had submitted an amendment. But it works out better for them, and because we want to keep them working with us on this, we will sacrifice those couple of weeks for that.

MR. ENSMINGER: My question is how did the initial health survey morph into a pilot?

MS. RUCKART: Well, we were considering the comments
made in the NRC report. We are trying to -- just
because of all the comments we received, you know,
we have NRC comments. We have comments from expert
panels, both the water modeling, and we have one,
last March I believe it was, to get some direction
and guidance for our future studies.

So I guess the Agency wants to be responsive
and yet also, we don’t like some of comments and
recommendations in the NRC report. There’s certain
recommendations that we don’t agree with and are not
comfortable with, so we are not going to be
following them. But when there are things that we
are comfortable doing, we don’t want to just totally
ignore the report. So --

MR. ENSMINGER: Why not?

MS. RUCKART: The Agency management feels that --

MS. SOWELL: The pilot gives us an opportunity to
fine tune things in the health survey study like the
recruitment procedures, to make sure that what we
have planned for obtaining medical records is going
to work out. It gives us a chance to smooth out any
rough edges before we actually start the full study
data collection process.

**MR. ENSMINGER:** But my point is that this health survey is not something that can be batted around between the NRC nor anybody in ATSDR. This is a law. It’s signed by the President of the United States, and it says this thing will take place.

**MS. RUCKART:** That --

**MR. ENSMINGER:** Now wait a minute, wait a minute. Damn it. This thing keeps getting dragged out longer and longer. Every time we turn around somebody’s throwing something into the mix that’s extending this thing for the answers that we’re looking for from the community. Now, this is another year at least.

**MS. RUCKART:** You’re right. What you’re saying is true. We did discuss this I thought in the August conference call that we had with you because it is in our final plan --

**MR. ENSMINGER:** I mean, that conference call, that conference call, you know, we get slapped with this stuff on a phone call, and we didn’t even have the report.
MS. RUCKART: Right, so we --

MR. ENSMINGER: We didn’t have your response until the minute that phone call took place.

MS. RUCKART: Right, so that’s why we --

MR. ENSMINGER: I mean, that was, that was unfair to begin with. I mean, why wait until the minute you’re going to make the conference call to give us the materials that you’re going to cover in the conference call?

MS. RUCKART: So we had a follow-up call I believe it was a week or so later.

MR. ENSMINGER: Well, I was too busy to do that again. But, you know, I’m airing my problems right now. This is crap.

MS. RUCKART: Well, all I can say is this is our new position. We have to move forward with it. And I want to address your question about this being congressionally mandated, so why are we going to be testing procedures and things like that. So that’s true. It is congressionally mandated so we’re going to go down the path, as Anne was saying, to just test out certain procedures, make sure that, as Anne
PILOT HEALTH SURVEY

So I guess we can start talking about the pilot health survey now. We may have to finish discussing it after lunch. But actually, the pilot health survey is going to employ basically the same procedures as the full health survey but be done on a smaller scale. So we estimate there’s approximately 300,000 participants for the full health survey.

So we would be testing the methods on a ten percent sample, approximately 30,000, and those will be selected to represent the different water systems. So we don’t want to just say, oh, we’re going to just take any old ten percent, 30,000 people. We want to make sure that we’re getting a representative of people who were on different water systems and civilians and dependents so it’s a good mix of the full population.

We’ll be employing basically the same procedures that we talked about all along in terms of our introduction letter to the survey and the
intervals we’ll contact them if we don’t hear back to try to increase their participation. We’ll try to confirm the cancer cases and other reported conditions as we’ve discussed before.

I would say the one change is we’re not going to send surveys to the known decedents as part of the pilot. They’ll be flagged, and they can be contacted later on when we do the full health survey. So that is one slight change.

Also, during the pilot when we have our phone contact, if somebody ultimately does not participate after these reminder postcards and reminder letters and we get to the point where we’re going to contact them by phone as one last attempt to gain their participation, we would ask them if they would share with us their reason for not participating and then this could help inform us to maybe make some tweaks for the full health survey.

So, we’re going to collect all this information in the pilot, what are we going to do with it? How are we going to make a decision to say what fine tuning needs to be done? Was it successful or not?
We’re going to convene an expert panel. We’re going to invite external epidemiologists to help us come up with how best to evaluate this.

We can do that while the pilot health survey is underway. We’re not going to wait for the data because we’re going to have criteria established ahead of time so that when we get the data we’ll be able to say whether the pilot was successful in terms of how many people participated, in terms of whether there was significant selection bias.

Some questions that the pilot can answer are: Did more people participate from Camp Lejeune than Camp Pendleton? How successful were we in verifying self-reported cancers? Is it likely that people with diseases participated more than those without diseases, and if so, what would be the impact on the results?

And then if, using whatever criteria are established, it is determined that it is not advisable to move forward with a full health survey, then, because as you mentioned this was congressionally mandated, we will still mail out
surveys to the rest of the population however, it
won’t be done as a study, and there will not be
these intensive efforts to get them to participate
or to confirm their cases.

MR. ENSMINGER: This is something that we touched on
with our initial thing about the CAP, and, you know,
the community members versus the experts. And the
one thing that, the one dividing line here between
the community members and the researchers -- and I
didn’t mean to feel like I was attacking you -- my
frustration is that as a community member, and a
very active one, and Jeff and Mike and Tom and Sandy
and Allen, you know, we talk real world with the
people that have been affected by this.

We’re not dealing with numbers and facts and
figures every day. And we’re not secluded or
sequestered into an office where we’re just dealing
with these numbers. We’re talking to these people
every day. I mean, and there’s a world of
difference when you’re talking to these folks, and
you try to make sense of, well, why are they doing
this this way? Why is this going to take another
year or a year and a half before we get answers?

There’s people out there dying. That girl right there is one of them. These people want answers. And every time we turn around there’s some other lengthy thing that’s been thrown into the mix. I mean, that’s my frustration with this pilot thing is this wasn’t part of the proposal initially, and all of a sudden this pops up.

I mean, it just seems like somebody’s trying to build in delays into this thing every time we turn around. And for lack of a better term, it’s B.S. I’ll clean it up.

MR. STALLARD: You said crap. I was thinking we could do an acronym. It’s creditable, reputable, applicable and prudent.

DR. BOVE: Let me try to bring transparency to this issue, too. I may get in trouble, but that’s tough. I’m opposed to doing a pilot. I think it’s unnecessary.

When we submitted the health survey study package to OMB, it had already been peer reviewed - the health survey study protocol had been peer
reviewed and it was approved by the CDC IRB. This approved study protocol and OMB package had no pilot as part of it. So before the NRC report came out we had a package at OMB with no pilot.

The reason we didn’t have a pilot is because we were going to be using the standard technique that’s used in these kinds of mailed surveys which is called the Dillman Method or modified Dillman Method. There is no better approach to doing a mail survey study that’s out there than this approach.

When we received the contractors bid to conduct the survey study, some of them recommended a few variations on the Dillman Method that they, you know, each contractor said that what they do is slightly tweak it a little bit this way, a little bit that way. But essentially the approach was going to be the Dillman Method that they felt comfortable with, their version of it, because each one of these contractors have a lot of experience doing survey research. That’s why they bid on it. And they all use some variation on the Dillman Method.
So why a pilot? When we had the March 2008 meeting of epidemiologists, and Dick was there so he can correct me if my memory fails me, the notion of doing a pilot was mentioned at that meeting. And there’s differing interpretations of what reason it was raised and what the purpose of that pilot was.

And my interpretation was that at that point we weren’t sure, there was no mandate at that point to do the survey yet, right?

MS. RUCKART: That came out in January.

DR. BOVE: That came out in January. And there was some concern as to what method might bring out the best participation, e.g., monetary incentives or a letter from the Marine Commandant. So there was some talk of trying to pilot that to see what would increase participation.

So that was mentioned at the meeting. I think that was the main thing, there was some concern about medical record confirmation, but I don’t think there was a discussion about piloting that. I think the main -- if you remember --

DR. CLAPP: That’s right. That’s how I remember it.
DR. BOVE: It was participation, which is an issue. I mean, we want a high participation rate. We were asked when we were challenged internally to come up with criteria for what is a successful survey, what was a participation rate that means it’s a success. And so I searched high and low, and I found a published study that had 25 percent participation rate in the exposed group and 12 percent participation in the unexposed group.

And that was published in a reputable journal, or somewhat reputable, The Journal of Occupational and Environmental Medicine. It is a peer review journal. So that gets published. There appear to be no hard and fast standards for participation rates. In the early ’80s, 65 percent, maybe 70 percent, was considered a minimum participation rate, but as time went on it kept dropping.

And now, for example, the Millenium Cohort Study, which is a military cohort study, the initial participation rate was around 40 percent or so or even less. And the participation rates for the Gulf War studies varied. Some had high participation
rates in the 60s and some had in the 40s, but it
looks like what mailed surveys are getting these
days is somewhere in the 40 percent range, 40 to 50
percent, although there are published studies that
have participation rates much lower.

So I guess you could make a case that it’s
important to do a pilot to see if we can improve
participation. For example, a pilot could determine
if a letter from the Commandant was sufficient to
get a high participation rate or whether we’d have
to move to a monetary incentive. So there’s one
argument for a pilot.

Again, we didn’t propose a pilot before the NRC
report. The NRC report never asked for a pilot.
The NRC report basically said that none of these
studies were really that feasible, even the
mortality study they said was feasible, then they
said we wouldn’t have statistical power. They were
incorrect in that, but they were criticizing both
studies not just the survey.

Keep in mind that the real issue is not
participation rate. The real issue is, is there a
bias. You could have a low participation rate and
very minimal bias and a high participation rate and
a lot of bias. Whether or not there is selection
bias depends on whether people who are both exposed
and have the diseases that you’re interested in are
more likely (or less likely) to participate than
people who are not exposed and do not have these
diseases. So what you hope is you have a high enough
participation rate so that this bias is less likely.
With a low participation rate you have to make a
strong case for why this bias is not likely to have
occurred.

MR. ENSMINGER: Well, if they keep delaying this
stuff, you’d probably do away with the survey and
just do the mortality study because I think what
they’re doing is trying to delay this thing so that
everybody dies.

DR. BOVE: With the delay -- to hurry up here, the
other issue for the pilot was can we confirm cases,
and that’s another reason why we’re doing the pilot
apparently. What the pilot will do will delay one
year the completion of this full survey. So if we
did the survey instead of the pilot, we’d be done a
day earlier instead of if we do the pilot and the
full survey. So that’s the implication.

But in between we have to deal with OMB still
and funding.

**MS. RUCKART:** And then also getting the cancer
registries on board, just beginning the process of
formalizing that so they will be able to confirm
what’s reported.

**MR. ENSMINGER:** So now we’re looking at the
mortality study and this pilot survey are going to
be delayed, what, four-to-six months now because of
funding, say six months. Then the pilot survey is
going to add another year to a year and a half,
well, maybe even more. So there’s two years.

Where’s this heading?

**DR. BOVE:** What we think if we get funding in a
timely basis in the next few months, the mortality
study takes a little less than two years to
complete. That’s how long it takes; that’s the
normal rate. And then the survey will take three
years, the first year for the pilot, then two years
to finish the full survey, if the full survey is conducted.

And remember what Perri said is true. We’re going to set up a panel of expert survey researchers, and they are supposed to come up with criteria before we even look at the data, criteria for what would be a successful survey. Based on my own research into this there are no criteria. They’re going to have to come up with them in some kind of Delphi process, I guess, or some kind of consensus. But as far as I know there are none, but that’s what we’ve offered to do.

We also have said we would do certain analyses to tease out from the data all the information we can about whether there’s bias, how much the bias would be to obliterate any findings that were positive, just to get a handle on whether it’s plausible that bias could explain any positive results we find.

So that kind of analysis is not done that often but has been done, for example looking at the effects of smoking where you’re looking at lung
cancer and occupational exposure and try to see how much confounding there’d have to be to explain a finding.

Usually there isn’t that much confounding. And we would do something similar, an approach to see how much selection bias there would be, have to be so that a positive finding would be explained by that bias.

MR. ENSMINGER: Well, the military can’t say much about smoking any how. They used to provide cigarettes with our meals so for god’s sake, you know.

MS. RUCKART: I just want to say one thing. Frank was giving like in general it takes this long or it takes that long. I wanted to kind of ground that into calendar years for you. So if we’re able to start the mortality study very soon, the next few months, this year, we’re projecting a completion date of like summer 2012 for that. Fiscal Year...

DR. BOVE: Before you do that let me. This is the timeline, the most recent timeline. We’re talking by July of 2011. A lot of things, this is -- before
I even say that --

**MR. ENSMINGER:** Read that thing quick, Frank. It keeps moving.

**DR. BOVE:** Yeah, well, part of the problem with it keeping moving, part of the problem is the complexity of modeling Hadnot Point. That’s part of the issue here. A lot of things depend on us getting preliminary data from Morris. A couple months ago it appeared that we would get preliminary results from the Hadnot Point modeling in October of next year. Now it’s moving to November, December.

   So it’s creeping, and I have a feeling it’s going to creep a little more. As that creeps, it pushes the timeline, that in itself pushes the timeline, just the complexity and difficulty of Hadnot Point. There’s nothing we can do about that.

   It’s a very complex situation where we are doing cutting-edge stuff, we have experience at Tarawa Terrace, but this is different from Tarawa Terrace. And it’s different from any other situation I’m aware of in terms of water modeling and exposure assessment. We’re in the frontier so
you have to expect that there probably will be some
slippage of the timeline just because of that.

But if Morris provides data to us let’s say by
December of next year or January of 2011, several
things can be finished before the end of 2011 and
that would be the mortality study and the re-
analysis of the small for gestational study and the
analysis of the case-control study of specific birth
defects and childhood cancers. The re-analysis of
the small for gestational age study and the analysis
of the case-control study are totally dependent on
getting that Hadnot Point monthly contamination
estimates and modeling that interconnection between
Hadnot Point and Holcomb Boulevard. Once we have
these data, these studies can be finished quickly.

The NRC report said that we should not wait for
the Hadnot Point modeling results, but instead,
finish these two studies now. If we did that, we
would make the same mistake again as we did with the
original small for gestational age study. So we
don’t want to do that. We want Morris to finish, at
least providing preliminary data we feel comfortable
with, and then we can run with it. So that’s the idea.

The mortality study also will be affected by that water modeling delay, too. But it’s also the funding issue and when we get that funding. So there’s two things going on with the mortality study. Is that being clear?

(no response)

DR. BOVE: The health survey is this way. It’s unclear to me whether we would have gotten OMB approval for the full survey or not. It was unclear. And right after the NRC report we weren’t sure, and though we had a good conversation with OMB, they didn’t say definitely positively. We came back with a pilot that changes things. That’s why we had to pull the survey and re-apply with the pilot. So that’s how that works.

MR. ENSMINGER: Well, the foundation for everything that’s going to happen at Camp Lejeune and has happened at Camp Lejeune like the in utero study and all the studies that will go forward from here on out, the foundation for everything is the water
model and without it there’s nothing.

**MR. STALLARD:** So we need the funding for that.

I’m going to use this as an opportunity to
discontinue the conversation because we have lost
our feed during lunch. So let’s take a break and
come back. I’d like to invite Dr. Clapp to comment
on his perspective on the pilot, and then we’ll
finish with Frank’s presentation. One hour.

(Whereupon, a lunch break was taken from 12:02 p.m.
until 1:00 p.m.)

**MR. STALLARD:** We’re going to continue to talk about
the future studies but what I would like to do is to
invite Mr. Thomas Kniffen, who is from the VA. I
have been remiss. I think I should have invited him
to sit with us earlier because it has long been our
intention to have a representative of the VA. And
this man has come here to be that for today.

And so if you would, join us at the table.

And then he’ll have his presentation, and we’ll
make his introductions at that time.

And so welcome and thank you for being here and
we’ll go to formal introductions shortly with the
So we left off with a dialogue about the pilot study. I asked that when we came back there were two things I’d like to know, get more information on. I would like to hear from Dr. Clapp about it and maybe a little bit more information about the role of OMB. They’re a big player in this and why working with them is important to everyone.

**DR. CLAPP:** I said before the break that I’ve done studies of veterans where we looked at both deaths and cancer incidence. And we’ve never done a pilot study before you embarked on it, but both those were funded at the state level. They were state Office of Veterans Services level and not federal funds. So there was no OMB involved. So I can’t really comment on the difficulties that are put in place by having to go through an OMB review or an OMB process before starting a study.

All I can say is that in my experience you make a decision on what it is you want to study and what the population is that is of concern. And then based on an approval of that, you go ahead and do
the study, and it isn’t necessary to in all cases do a pilot study.

I think that the train has left the station though as far as this particular OMB request. It’s going to be first for a pilot study and then revisited later on. So I don’t know what to say about how, what we can do at this point in the state of things. It seems like it’s a done deal.

MR. STALLARD: All right, well, we have here Frank, Perri, Dr. Clapp and we still have to talk about funding, congressional briefing, cancer incidence, male breast cancer.

MS. RUCKART: We talked about that.

MR. STALLARD: All of them?

MS. RUCKART: We talked about the funding.

CONGRESSIONAL BRIEFING

MR. STALLARD: Let’s talk about the congressional briefing.

MS. SIMMONS: Could I just ask a question about the pilot study? Didn’t you all do one of those before for I think the current study that’s going on?

MR. ENSMINGER: The in utero.
MS. SIMMONS: That’s what I was thinking. Right?

MS. RUCKART: Well, that wasn’t really a pilot.

That was, well, we had to ascertain the cases so --

DR. BOVE: I think there was something done prior to the survey itself. Is that what you mean?

MS. SIMMONS: That’s what I was --

DR. BOVE: Yeah, and I think the issue there was whether we could find people. For example, you do a pilot when you’re not sure whether you can locate the people you want to sample. For example, if you were doing a study of people who lived in FEMA trailers after Hurricanes Katrina and Rita, they scatter around. You may not be able to enumerate them all to get a sampling frame.

So a pilot can be conducted to determine whether we even have an idea of who was there and whether we can locate them. So for Camp Lejeune we have the birth certificates, but we wanted to expand it to those who were pregnant on base but who left the base before giving birth. Well, if the parents gave birth outside North Carolina, the birth certificate data for NC would not have this birth
and we would not know about it. And so I think that that was part of the reason for the pilot - to see how you would find these births that occurred off-base in another state. And the other issue was could we actually locate and contact the parents of children born on or off-base. We have birth certificate information. Now we’re contacting them a long time afterwards, you know, can we contact them?

For the health survey, for the people who are in the DMDC database we have social security number and data of birth. So locator firms are much better now than they were even back then. So with that information it’s pretty clear that you could identify and try to contact them.

So the question -- and another issue with a pilot could be -- and we haven’t talked about this -- but there are people who are in the 1999-2002 ATSDR survey who we want to send a health survey to where we don’t have social security numbers. It’s not a large group but there are a couple thousand or so I would say. I’m not exactly sure, but five, ten
thousand maybe, somewhere in that range. So that
could be piloted. Can we identify the current
mailing addresses?

And then for the people who register with the
USMC, I’m not sure what information is being
collected, so that could be another thing to pilot.
But what we decided to pilot instead was to pilot
not necessarily could we find these people and send
them something, but how many would participate in
the survey, because that appeared to be the chief
concern - NRC’s concern, others’ concern. Who would
participate and who wouldn’t participate?

MS. RUCKART: Frank, we’re including the way to find
them in the pilot.

DR. BOVE: Well, okay.

MR. STALLARD: Sandy, would you mute your phone,
please?

DR. BOVE: Tom Sinks and I and Tom Frieden, who’s
head of CDC, met with Senator Burr and Senator Hagan
and their staffs about three weeks ago, for about
40, 45 minutes and were asked a number of questions
about funding, about what our statutory authority
was and some questions about the survey. So we did that.

And we had a call with them yesterday to follow up on some of the issues around funding. Funding is the key issue. So that happened. Any questions on that?

**MR. STALLARD:** Yeah, what was the atmosphere like? I mean, how did it go?

**DR. BOVE:** Well, the atmosphere was that the two senators and their staffs support our studies. They support our getting funding for the future studies. They support the water modeling effort. They think it’s important that those who were at the base, either the Marines or their dependents or civilian workers, have a right to know what happened, and they want answers and so on. So they feel that our water modeling and our studies will help provide this answer. So that is their...

**MR. BYRON:** Are you getting any -- this is Jeff. Are you getting any other congressional inquiries into this or...

**DR. BOVE:** That’s all I know about is these two
briefings we’ve had with Hagan and Burr’s staff. Hagan and Burr are North Carolina senators. One’s a Republican, Burr, and the other Democrat, Hagan.

**CANCER INCIDENCE STUDY**

**MALE BREAST CANCER**

So we’ve talked about everything but the cancer incidence study and male breast cancer situation, and I think that they’re kind of linked to some extent.

Did you want to say something about it at this point, Mike?

**MR. PARTAIN:** Well, we continue to find out about more male breast cancer cases. Actually we’re up to 51 now. Mrs. -- I don’t know if she had to leave or not.

**MS. RUCKART:** She’ll be back.

**MR. PARTAIN:** She’ll be back? And I apologize if I mispronounce her name, Appalooto (ph)? Her husband was at the base, and she’s here today in the audience. And he was diagnosed with male breast cancer in his early 60s and passed away in 2006.

So I know with the attention we’ve been getting
through the media, we’ve been finding quite a few cases. I mean as early as June this year we started out, we had nine or ten that I had found, and then once we got the media involved we’ve jumped to 51.

And one of the things we want to look into, I mean, you know, one of the things we want to look into is this, you know, occurrence rate to try to get an idea of how many cases we could expect to see. And one of the reasons I bring that up is right after the hearing last week, and the NBC story in particular, I received a phone call from a news agency informing me that Headquarters Marine Corps, a major had called in and quoted a occurrence rate for male breast cancer at one in 1000 in the general population, and therefore there should be 400 cases of male breast cancer present at Camp Lejeune, and there’s really no cancer cluster or any type of abnormality in the fact that we have so many men with male breast cancer. And I find that disturbing. I didn’t know that the Marine Corps was in the business of epidemiological studies and such.

MR. ENSMINGER: Not according to their general
staff.

**MR. PARTAIN:** And unfortunately one of the news agencies actually published this statement by the USMC that 400 cases would be expected based on the 1 in 1000 figure. It’s my understanding -- and I’m not an epidemiologist myself -- but my understanding in talking to you and Dr. Clapp and some of the other people out there including Dr. Davis, you know, they quote the SEER rates, statistical rates for male breast cancer is like 1 or 1.06 in 100,000 people, which is a pretty small number.

So is there something that ATSDR can do maybe working with some of the other agencies to help identify just what would be expected or what kind of rates we’re looking at to see if this is something that is abnormal.

**DR. BOVE:** Well, it’s very hard to know how many expected when we don’t know how many were exposed, how many were at risk. The 400,000 figure, my guess is that when we first got data from DMDC -- well, we didn’t get it -- when the Marine Corps first got data from DMDC for the ’75 and ’85 years, there were
about 200,000 people in it. And they figured, well, okay, that’s 200,000 in that ten year period and
200,000 in the ten year period before, so from ’65 to ’85, let’s say 400,000.

Of course, that leaves out dependents and so on. But it also includes people who may have been at other parts of the base where exposures didn’t occur or whatever. So we don’t know. That’s the first question – how many people are in the exposed population that we’re concerned about? We cannot determine the number of male breast cancer cases expected if we don’t know the size of the exposed population.

The second issue is, and Dick and I were just talking about it, is the incidence rate of one per 100,000 person-years for male breast cancer. This incidence rate is averaged over all age groupings. Now, you know, an average is a good summary measure, but it hides things, too. Any average does.

In the early age groups, the incidence rates are much lower than 1 per 100,000 person-years. And as you get older it’s higher than that, and the
average is averaging all together, right? So you would like to know since this population -- well, at least from '75 to '85 are younger than me -- for example, what the age specific rates for male breast cancer are. So that would be something that we could probably get from SEER if they’re willing to part with the data. I think part of the issue might be --

MR. ENSMINGER: It’s already there.

DR. BOVE: Well, by age-specific for male?

MR. ENSMINGER: Yes.

DR. BOVE: Okay, because I haven’t seen it.

DR. CLAPP: It’s not published, but they have it.

DR. BOVE: But they have it, yeah. They don’t publish it because probably it’s based on small numbers.

MR. ENSMINGER: It’s less than two for any age group.

DR. BOVE: Less than two what?

MR. ENSMINGER: Per 100,000.

DR. BOVE: Well, it’s one per 100,000 average over all the ages. I should think for ages 35 to 55
It’s considerably less than one per 100,000.

MR. PARTAIN: It’s my understanding the younger the diagnosis, the more rare it is.

DR. BOVE: Absolutely.

MR. PARTAIN: I mean, that’s something that ATSDR can contact SEER and even I know the EPA is working on PCE and TCE risk assessments, so they probably have some data that you guys can get from them.

DR. BOVE: Again, we could play around with numbers. We don’t know, and there’s no data on how many people were at the base between ’65 and ’75, and then there’s no data on how many dependents were on the base from ’75 to ’85 or before 1975.

You can get a sense maybe from the high school data in microfiche, which are falling apart and disintegrating, so you can’t really utilize that data. And so it’s difficult in other words to figure out how many, how large the exposed population is. That’s the first issue.

Then --

MR. PARTAIN: Do a quick look. I mean, there’s got to be some type of --
DR. BOVE: Yeah, we can come up with some scenarios. I did one over the phone with you, and I’ll share it with everyone for what it’s worth. You have 400,000 people from ’65 to ’85, probably based on the DMDC data that indicates about 200,000 Marines and Navy personnel were at Lejeune anytime between 1975 and 1985. So, just let me play this out because that’s where the 400,000 came from I think.

MR. PARTAIN: We don’t know where it came from. I don’t know where Marine Corps pulled that out.

DR. BOVE: Well, let’s assume that’s where it came from. So 400,000 people, you’re following them. Take the middle of that period so it’s 1975. You’re following them ‘til now, which is 34 years. So then you factor in a 20-year latency period. And so if you do all that, you end up with probably you’d expect about 60 cases. Now, there’s all kinds of problems with what I just said.

MS. SIMMONS: Four hundred thousand?

DR. BOVE: Yeah, what we should do, it’s person-years, one case per 100,000 person years. You follow 400,000 people up to now, let’s say, and some
of them are in the ’65 to ’75 period. Some of them are in the ’75 to ’85 period, figure they’re evenly distributed.

Take the middle year, ’75, -- I’m playing around. ’Seventy-five ‘til now is 34 years, right? Lop off about 20 years to take into account a latency period for the cancer, and you get something like 15 person-years times 400, which is six million person-years, which gives you 60 cases. So we can play that game. But, again, keep in mind all the assumptions I just made. In any case, it’s not 400, okay? It’s not 400.

MR. PARTAIN: Or even 60. I mean, 60 sounds high.

DR. BOVE: If we could get some good data on the size of the exposed population -- and the other issue here is we haven’t ascertained all the cases. That’s the other side of the coin, right? I mean, you’re getting people contacting CNN, but there’s a lot of people who didn’t watch that show.

I wouldn’t have watched it, for example, if someone didn’t tell me it was on. I don’t watch Campbell Brown or even NBC Nightly News for that
matter. I would have missed it. I could have missed this all kinds of ways. We haven’t ascertained all the male breast cancer cases from Camp Lejeune, I’m sure. So that’s the other side.

**MS. RUCKART:** But when you’re talking about your rough estimate of 60 cases, that’s just --

**DR. BOVE:** I don’t want to get quoted on that. It was just a hypothetical scenario.

**MS. RUCKART:** Okay, but you’re not talking about necessarily factoring in their exposure. That’s just what you would expect for 400,000 people.

**DR. BOVE:** Well, I’m assuming in this scenario that there were 400,000 people exposed to Hadnot Point water or Tarawa Terrace water. If they were just like the general population, how many breast cancers would we expect in these 400,000 people? That’s what I was trying to do, but there are a lot of problems with making this estimate. If we can get better data on -- well, first of all, we need to find out how far back in time the Hadnot Point water system was contaminated, how high the levels were how far back in time. So that we need to wait for.
I know Scott Williams has been trying to figure out how many people were on base over the years.

There was a lot of consternation when I said to the press a couple of years ago that it could be up to a million, 750,000, a million. I was playing this numbers game that I just played with you now. When you actually start trying to find data on this, you find that there isn’t much to go on. And when you come up with different scenarios, actually you turn out that what I said wasn’t that far off or off at all.

But the problem is the data’s not there. So you’re going to have to use all kinds of different assumptions as to how many people went through the base and which water system we’re talking about. If we’re talking about Tarawa Terrace it’s considerably small.

MR. PARTAIN: Let me ask that. Can we go ahead and try to nail down some type of population figure just to kind of give us a rough estimate to give meaning to what we’re looking at with this.

DR. BOVE: Four hundred thousand sounds as good as
any number out of thin air. We can just come up
with a number, but it will not be based on a whole
lot of information.

MR. STALLARD: Tom, go ahead.

MR. TOWNSEND (by Telephone): I disagree with Frank
on finding the population figures. I have the
document that shows the quarters I lived in for a
period of 20 years. It was a printout that came
from the Base Housing Office.

Now, if we know from the unit diaries how many
troops were living in those, in the barracks, and I
damn well know that every set of quarters on that
base -- it included Tarawa Terrace after a certain
point in time -- every house had a number and the
Marine Corps knew the people who were in it. And
the only time that the population dropped the
dependents was during Viet Nam when they may have
dropped but they tried to keep people in them.

And the Marine Corps certainly knows what units
they called up at Camp Lejeune for Viet Nam. I
mean, there was a drop during Viet Nam of the active
duty people, but I don’t think the houses were
empty. I think people were allowed to stay in them.

Like I said, I just don’t buy it. I figured about a million or a million and a half people have lived in that place over that period of time.

DR. BOVE: What we were missing, Tom, is not the housing, family housing information. We have the family housing information and can make some estimates based on that. What we don’t have is the barracks information.

MR. TOWNSEND (by Telephone): What happened to the unit diaries?

DR. BOVE: If you have this data, then you ought to give it to us because we don’t have it.

MR. TOWNSEND (by Telephone): I don’t have the bloody unit diaries. The Marine Corps should have them.

DR. BOVE: I thought it was, I would like to see any estimates that the Marine Corps has. That would be fine. What I’ve heard informally is that you have to make a whole lot of guesses because the data’s not there. Now, that’s what I’ve heard. I don’t have access to this data either, Tom.
You’re right about family housing. If we want to know how many people were in Tarawa Terrace, we could make some educated guesses based on how many housing units there are and how many people were there in each unit and how often the turnover was. That can be done pretty easily.

MR. ENSMINGER: Well, and Tom, hey, Tom?

MR. TOWNSEND (by Telephone): Yeah, I’m still here.

MR. ENSMINGER: This is Jerry. You know, in reality we wouldn’t even need the unit diaries. All we would need is the Command Chronologies, and I know damn well they exist.

MR. TOWNSEND (by Telephone): I know they do.

MR. ENSMINGER: I mean, the Command Chronology shows what the unit rates, what their actual strength was, shows new joins, drops. It shows everything in the Command Chronologies. And as much as the Marine Corps loves its history, I know damn well those Command Chronologies are available.

DR. BOVE: I think that we can come up with a couple of scenarios and play around with these numbers, but the other question is this. What would be useful in
trying to get an understanding of this group of men. What kinds of questions could be asked of these people that would help us understand what kinds of activities they had on the base that would inform not only their situation but could also inform the future studies in general.

It’s always useful to hear from people who were at the base just what they did on base because there have been activities such as how long, you know, how often they did calisthenics or what they used to clean their rifle or what jobs they did and what kinds of experiences they had on those jobs and so on. So there’s information that would really be helpful, not only to get an understanding of them, but as I said, would be useful in general for our studies.

So I would suggest that some of us work together to come up with some kind of instrument to -- whoever wants to do it. Devra Davis is doing it or whoever wants to interview these cases that we’d ask the same questions, try to elicit this information: when they were on base, where they
lived, how long they lived on base, what kinds of activities on base; really get a handle on what their life was like on a daily basis at the base.

**MR. STALLARD:** Would that be --

**MR. TOWNSEND (by Telephone):** What population are you asking these questions though, Frank?

**DR. BOVE:** Sorry, Tom?

**MR. TOWNSEND (by Telephone):** What populations are you asking these questions of?

**DR. BOVE:** Well, first I would want to just do the cases that have been self-reported or --

**MR. ENSMINGER:** He’s just talking about the male breast cancers right now, Tom.

**MS. RUCKART:** Wouldn’t this come out as part of the health survey if these people --

**DR. BOVE:** Well, this is a little bit more information, I think, than we’re asking for in the health survey. So we are asking people where they lived and where they worked on base. So that’s part of the health survey. So, yes, we would get some of this information.

But I was thinking it would be interesting to
get even more information on their activities if we
could because they’re interested. They self-
identified themselves. I think it would be useful
if they were willing to do that.

MR. PARTAIN: Yeah, most of them are.

MR. STALLARD: Part of what’s going on is that we
have a bunch of people who are stepping forward now.
And there’s going to be some expectation of
something I would imagine. And so what you’re
suggesting is that there may be an opportunity to
engage these people in a more meaningful way to find
out what their activities were so that they’re not
just identified and waiting for something. Is that
what I’m hearing?

DR. BOVE: Dick, did you want to weigh in here?

DR. CLAPP: Yeah, I’d actually like to ask Mike,
what kind of information are you collecting, or is
Devra checking the diagnosis and more or what?

MR. PARTAIN: And Devra on the original group, she
did check on diagnostic reports. Of course, when
she wrote the initial report, we only had nine or so
and then it’s blossomed up to 51 now. But when I
contact the families of those that are deceased and the current, the ones that are currently living, I try to find out where they lived when they were on the base, what they did in the Marine Corps.

And I’m asking these people, I’m not asking for it right now because I don’t feel that it’s really my position to get a copy of their D-214 and their diagnosis. I ask them to see if they can find it so when they do the studies, the scientists are looking to verify these things, can get that documentation. That’s what I’m doing with just that group there.

One thing I want to jump back on with the male breast cancer issue, I mean, by no means this is not the only rare cancer that we’re getting reports of on our website. Non-Hodgkins lymphoma, which if you go back to the NRC report, shouldn’t be happening. We’re getting a lot: non-Hodgkins lymphomas, leukemias, bladder cancers, kidney cancers, liver cancer, thyroid cancers.

So the reason why this male breast cancer issue has kind of stepped out and taken a different form here is because it is extremely unusual. It’s a
rare disease, and you’ve got men who are supposed to be in the tip-top physical part of their lives, you know, the Marines, the roughest, toughest bunch in the world, coming down with a rare disease that’s normally associated with women.

And by the way, we have tons of women, female breast cancer coming that step forward, too. So and one of the things I, and the point I want this cluster that has shown up is that to me it’s indicative that something happened on the base. There is an adverse health effect that has shown up.

You’ve got a cancer occurrence that shouldn’t be happening, and one of the questions that’s been fed back to me and asked is just how rare it is. And that’s what I’m trying to get at here is how rare is this cancer. Should we be seeing 51 men? And the other big thing, too, that I’m understanding is that most of these men, I want to say about 22 to 23 of the 51, were diagnosed under the age of 56, which is another oddity.

We’ve got two children who were born in the same year, off base. Came on base and were exposed
on base. One was diagnosed at 18 with two separate breast tumors, had a double mastectomy. A second child came on base after he was born at the naval hospital, lived on base for two or three years. He was diagnosed at the age of 18 -- I’m sorry -- 20, with an actual breast cancer tumor.

And for a 20-year-old male and an 18-year-old male to develop this disease is almost statistically unheard of. And even my case, you know, I’m 39 when I was diagnosed. That is extremely rare, and to have these men in their 30s and 40s being diagnosed, my understanding talking to people such as yourself, Dr. Clapp, and Dr. Bove, that is indicative, it would skew the numbers to have these younger diagnoses to make it even more unusual and more, stand out even more.

**DR. CLAPP:** While I have the chance, I did have to talk to Mike to look up the SEER Program. And their statistics for age-specific incidents or even age-specific probability of diagnosing cancer, for breast cancer it’s only published for females. But they do give --
MR. PARTAIN: And why is it published for only females?

DR. CLAPP: Because it’s so rare in males. Then they do give this other table that is an estimate of the U.S. prevalence for the year 2006. This is from their Prevalence Report. And actually, this would be cases alive and living with breast cancer in the year 2006 whenever they were diagnosed.

So they estimate for males age, actually zero through 19, there would be no cases in the U.S. And for those age 20 to 29, this is in the entire U.S., they estimate there would be 23 male breast cancer cases, and then it goes up. And they estimate a total of -- and this is again one year, live, living with breast cancer -- 13,132 male breast cancer cases of which more than half are age 70 and above, and then a smaller number between 60 and 69 and then much smaller numbers as you go back down.

So this is their estimate that is published, and it’s based on --

MR. PARTAIN: It’s based on the population of the entire United States. So from zero to 19, you said?
DR. CLAPP: Zero is what they had.

MR. PARTAIN: I mean age one to 19, zero cases.

DR. CLAPP: Right.

MR. PARTAIN: So, and we know where to get two, and two if you count 20, and then from -- what about 55 and below?

DR. CLAPP: They just have 50 to 59, a total of 2,078 cases; 40 to 49, 542 cases in the whole U.S.; 30 to 39, 75 cases; and 20 to 29, I said 23. So by far the bulk of the male cases would be over age 70 and even counting over 60, that’s almost 80 percent.

MR. PARTAIN: And coincidentally most of the male breast cancer cases that we have at Camp Lejeune are well under the 70-age frame.

DR. BOVE: Well, this is why I wouldn’t want to use the one per 100,000 because as I said it’s an average. You’d really want to know what the age-specific rates are because they’re much lower than one per 100,000 in those younger age groups. They’d have to be. But we can pursue this. We need to move on, but I can think of a couple proposals.

One is to get this information from SEER, and
we’ll try also our CDC people as well because they have other cancer registries, and they get data from a wider, larger group of registries than SEER does, and see what the age-specific rates are for male breast cancer. Like I said, that’s one thing we can do.

The second thing is I was proposing that some of us get together and come up with an instrument or talk to Devra Lee Davis first of all and find out what she’s doing and coordinate with what she’s doing to try to get more information about what experiences these men have had at Camp Lejeune. Is that something the rest of the CAP, does that sound like something...

MR. PARTAIN: Yeah, well, is there something maybe we can get in writing to like start the inquiry as far as, and that’s what my understanding that Dr. Davis was doing was basically a case history saying there are X number of men with male breast cancer that we have identified from Camp Lejeune, and throw it out into the scientific community so people can start looking.
DR. BOVE: Yeah, this is what I was thinking of - case reports. If we have case reports of 51 male breast cancer cases with an extensive exposure assessment, I think that would be interesting as well as all the other information that Dr. Davis was collecting, i.e., whether they were positive for the breast cancer gene, for example, and so on, all the other risk factors that she was trying to collect information for those few cases that they did look at.

Because I saw the preliminary stuff that she wrote up and there is some, you know, she was trying to capture that information as well. We could try to capture that for all 51. So we would want to try to come up with some kind of instrument that would ask them these questions, dove-tailed with what Dr. Davis is doing so we’re not, you know...

MR. PARTAIN: And we’d also like to get --

DR. BOVE: And that’s what I’m suggesting, is that something that the rest of you feel is a good idea?

MR. PARTAIN: And one thing we need to include, too, is I guess a formal request to the Department of the
Navy and the Marine Corps to produce some type of population census for the base I would say from the 1950s up to 1985, maybe provide it on a decade basis or something like that.

**DR. BOVE:** I’d like to see some numbers, but I would actually like to see what’s behind the numbers. There is some information about how many units were, how many services per water system, there’s some data that I know Scott was working with because he shared it with me a couple years ago. There’s some information and maybe we can see what, if you make certain assumptions, maybe we can clean up this so we have a better sense of how many there were.

We still would have a lot of uncertainty, but maybe we can justify a 400,000 figure because we’re making these assumptions, but it’s based on this information. So we could work together maybe with the Marine Corps on that if that’s something we can do. I’d like to do that.

**MR. STALLARD:** I’ve captured those three things about the SEER age-specific incidents of male breast cancer, working with Dr. Davis for an instrument for
a case history case report, something to get
additional information, and a request for some type
of population census for the years 1950 through ’85,
some data that we can see what this 400K is all
about.

Anything else in terms of updates?

DR. BOVE: We have to move on. I think maybe let’s
hold the cancer incidence study to a later CAP
meeting because it has been back-burnered for now
because our focus has been on the health survey and
mortality study. There are some issues with cancer
registries, some saying they can’t do a data linkage
without getting consent. Other cancer registries
have been able to do that as they do it for the Gulf
Wars study. So I think at a future date we may want
to have a fuller discussion of this.

MR. STALLARD: Is that all right with everyone?

(no response)

MR. STALLARD: Is that all right, the cancer
incidence? We’re going to talk about it at the next
CAP meeting?

MS. BRIDGES (by Telephone): Sandy. It’s fine with
MR. STALLARD: Thank you, Sandy.
And at some point during this discussion I’d like us to address there was some question about timelines that we heard. I don’t know, alternate timelines?

MR. PARTAIN: What timelines?

MR. STALLARD: I’m trying to understand the way, when things were going on at the base and things were known. What your research has said versus what the Navy chronology timeline --

MR. PARTAIN: What was the question, plus why are you asking the question? What came up or what concern came up? That’s probably better. Was something asked to you?

DR. BOVE: One of the things, yeah. At a future CAP meeting it would be good for you to go over your chronology. I know you’ve developed one, and none of us have actually, you haven’t presented it, and I think that would be something and another contribution --

MR. PARTAIN: We’d need an entire CAP meeting to
present things.

DR. BOVE: It may be interesting for your take on it, not just you but I know Jerry was involved in that, Jeff and so on, your take on the chronology.

MR. ENSMINGER: It’s not our take. This is made from very specific documents. So there’s no speculation. There’s no editorializing in it. I had to beat the hell out of him to keep him from editorializing.

DR. BOVE: Fine, whatever, but you’ve done a body of work, and at a future CAP meeting, I think that’s what we were talking about.

MR. STALLARD: It is what we’re talking about.

MR. PARTAIN: I mean the timeline, basically the research that went into the timeline was based on the Marine Corps and Navy’s documents and in the laying it out and making sense of everything. And, of course, we’ve gotten several versions of the Marine Corps’ timeline throughout this ordeal that morphs and changes depending on what document or what fact has been culled out.

But, yeah, I would be more than happy to do
that. Now, one thing I’ll note is the timeline is actually two parts. The first part is from the 1940s up to 1989. The second part is still, I’m still working on that --

DR. BOVE: When you’re ready. People have asked us, well, what does the CAP do, and this is one thing you have done among other things, and so it would be good to hear.

MR. PARTAIN: And one thing, you know, for those who are interested, the timeline is posted on our website and updated as we find new documents and new information pretty much on a regular basis. I think the last update was October 3rd, and you can download it. It’s a PDF document. And just whatever you want me to do I’ll be more than happy to talk about next time.

MR. STALLARD: Yeah, let’s talk about because I think that visually it gives us all a frame of reference. What is it we know. Instead of talking about it in the abstract. And then if we have an ah-ha moment in these meetings, like, oh, look, here’s a new document, we can place it in the
chronology of why is that important.

PRESENTATION AND DISCUSSION ON DISABILITY BENEFITS FOR
VETERANS WHO FILE CLAIMS RELATED TO CAMP LEJEUNE

So we’re going to move on now and introduce
Tom. So if you’ll give us a little background, why
you’re here. How is it you are able to join us
today?

MR. KNIFFEN: My name is Tom Kniffen, and I work for
the Department of Veterans Affairs. And I’m very
happy to be here today. I’ll give you a little
background on my job, what I do, who I work for. I
work in the Veterans Benefits Administration.

And the VA, if you don’t know, except for the
cemetery part is divided into two huge business
units. The first is the healthcare side, the VHA
part, and then there’s the Veterans Benefits
Administration, which is where I work. Even though
I don’t work directly with the healthcare side, I do
on occasion work with them on various projects.

My boss is the Under Secretary for Benefits,
Admiral Patrick Dunne, who reports directly to the
Secretary of Veterans Affairs. My day-to-day work
is that I’m in charge of the department that writes
all the regulations for the benefits side of VA,
whether it be on the adjudication side or the rating
side.

MR. MENARD (by Telephone): I can’t hear him. I’m
on the phone.

MR. TOWNSEND (by Telephone): I can’t hear him
either.

MR. KNIFFEN: I have a staff of four medical doctors
and four attorneys and three or four policy
analysts, and we, as I said, write the regulations
for the benefits side of VA.

I want to indicate to you how happy Secretary
Dunne is that we were invited today, that I’m here
on his behalf to answer your questions the best I
can. If you ask a question I don’t have the answer
to, I’ll try and get the answer for you.

MR. TOWNSEND (by Telephone): We can’t hear him.

MR. STALLARD: Just put that a little bit closer.
I’m sorry.

MR. KNIFFEN: If you have any questions that I
cannot answer, I will try to get the answers for
you, and I’ll try to answer your questions today.

First I wanted to talk about the slides that I brought today. When we were preparing these slides, we really didn’t know who the audience would be, what the composition of the audience is, so I think if I had known what I learned in the morning session and after talking to a group of people, some of you, we would have written these slides in a different manner, so I apologize for that.

Basically, I’d recommend that we move to page six because I think everything in between you already know. It’d simply be restating information that you already have.

I wanted to touch on a couple things that I took notes as I was listening this morning. First was a report that was issued by the Veterans Disability Benefits Commission, and I know there’s some disagreement in the room as to what that report said.

The Veterans Disability Benefits Commission, similar to the Dole-Shalala Commission, similar to the Advisory Committee on Disability Benefits,
similar to the ACVAR* Study of the 1970s. These committees or commissions were created by Congress or by Secretary of Veterans Affairs at the direction of Congress to study what we do and to take testimony from the public, from experts, statisticians and then develop recommendations and write a report.

Although we may provide testimony, and we may provide written inputs to their deliberations, we do not have any control over what they write. We may implement some of their recommendations. We may implement parts. We may implement none of a particular recommendation.

But my point is their report, which is about an inch and a half thick, is the report they wrote. They had a full-time staff I think for almost 18 months. So we’re not insensitive to your possible disagreement to what they said in their report, but we really had no, we had no control over their recommendations.

Now, on page six, page six of our slides where we start to talk about the NRC recommendations from
June of this year, I’d like to give you a little background as to how the Department of Veterans Affairs works with the national academies and the IOM reports that we receive.

Typically, what we receive are IOM reports from the national academies. We receive those reports because of a couple of statutes involving Agent Orange and the Gulf War. And I’ll give you, the most current example would be on Monday this week, the Secretary issued a press release indicating that he had decided to accept certain recommendations for Agent Orange presumptive service connection.

But that process started months ago when the national academies conducted a research project, a detailed report was written. When I say a report, it was probably an inch and a half thick.

What happens then that report is given to the Department of Veterans Affairs, and then we have representatives within VA from the healthcare disability side, the Office of General Counsel and the Office of Policy meet, study the report, and then make recommendations to the Secretary. The end
product is what occurred Monday in the case of Agent Orange. The point of what I’m trying to explain is that we rely upon the report from IOM. We study it internally, and then we make recommendations.

Now typically, at least since I worked at the VA, I haven’t seen the report from NRC and the national academies, but I’m equating it essentially to an IOM report as far as how we evaluate scientific data and outside reports. And the structuring of the 14 -- on page seven, the list of 14 conditions as limited or suggestive evidence -- I think that’s, I have a copy of the NRC report over in my chair, but I think it’s the first one down.

There’s five different levels of recommendations. This is the second one. We deal with their five levels all the time. Third, I’m sorry. So we evaluate based upon their ranking of different disorders just as the NRC did although we do it in the IOM reports. So in this case as you may know, we have convened a work group at VA to study these recommendations.

And the work group is composed of
representatives of Secretary Dunne, who I work for, is Under Secretary for Health, General Counsel’s Office and Assistant Secretary for Policy. That group will meet. I don’t know when they will complete their deliberations. It’s hard to say, six months, 12 months. They will make recommendations to the Secretary as to what to do or how to react to the recommendations from the NRC.

Now, this leads me to the method by which the Department of Veterans Affairs adjudicates claims for disability. We follow statutory requirements. There are federal statutes that tell us exactly how to address and adjudicate claims for disability. There’s two ways.

One method is a factually specific, veteran specific claim for disability benefits where the veteran has to show a current disease or diagnosis, and incident of service and then usually medical evidence linking the two together, the current diagnosis and the incident of service. If the veteran’s able to do that with or without representation, then typically the veteran’s awarded
what’s called service connection.

Once that happens we move into the next level of analysis which is whether it’s, to what degree it’s compensable, whether the degree to which the veteran is impaired. That’s one way to approach a claim for service connection.

The other way is what I refer to occurred on Monday or Tuesday of this week is something called presumptive service connection, and Agent Orange is probably the best example. Where going through the process I described to you with research that we receive from the national academies, we receive a report. We study it internally. We make a recommendation to the Secretary of Veterans Affairs ultimately makes the final decision.

We have a list of diseases or conditions which, for which an individual may receive presumptive service connection. You don’t have to go through this factually specific process of showing an in-service event, diagnosis and a linking of the two. It’s presumed to have occurred and service connection is established.
And the best example again is Agent Orange, and we are expanding our list of presumptive conditions based upon a decision Secretary Shinseki made, I think he probably made it last week, but it was made public on Monday. We’re not at that point yet. We’re not at the point where we would even make recommendations to the Secretary based upon the report that came out in June. I would call it the first step.

Regardless of what you think of the report, I know there was talk this morning of questioning it or debating it. I’m talking more now about the process, the route that we follow. The route that I’m describing to you is set by statute, and we implement it through our regulations.

Any questions?

MR. TOWNSEND (by Telephone): I’ve got some questions for the gentleman.

MR. STALLARD: Go ahead, Tom.

MR. TOWNSEND (by Telephone): I couldn’t hear him very well, but your name is Mr. Nixon?

MR. KNIFFEN: Kniffen, K-N-I-F-F-E-N.
MR. TOWNSEND (by Telephone): I have been in contact with headquarters of the VA since 25 March of this year, and the first contact was not mine. It was Tom Sinks as Director of ATSDR sent a letter to Admiral Dunne and asked him if he would cooperate. I sent material to Admiral Dunne on 15 May. Senator Feingold sent the information to General Shinseki on 6 July. I’ve been in contact with Admiral Dunne on 23 September and 30 September, and they’ve been dragging their feet like bloody god damn anchors. Now, am I going to the wrong place?

MR. KNIFFEN: Sir, I’m here to answer your questions, and I’m going to take your message back to the Secretary. I can assure you that our goal today is to participate in an open dialogue with the Department of Veterans Affairs, and that’s why I’m here.

And I appreciate your efforts making contact with Secretary Dunne, or the two letters Secretary Dunne received, and that’s why I’m here today. And I’m trying to answer the questions that were raised in the, I think the March letter to Secretary Dunne.
And I will take your questions and your concerns back to Washington with me.

MR. TOWNSEND (by Telephone): I’ll give you some quick background. I’m a 50 percent disabled 80/50 right now, okay?

MR. KNIFFEN: I’m sorry. I couldn’t hear the last part, sir.

MR. TOWNSEND (by Telephone): I’m a disabled veteran already. I’m a confirmed VA patient. I’m 50/80/50 diagnosis, okay? You got that?

MR. KNIFFEN: Yes.

MR. TOWNSEND (by Telephone): I went 18 months ago for a C and B exam at the Spokane Veterans Medical Center for neuropathy that my neurologist says was caused by exposure to VOCs. I have lost my wife and my son to what I think is VOC contamination. The VA in Boise, Boise, Idaho, said don’t examine Townsend for neuropathy. Try to make some bloody connection between radiculopathy and an injury I suffered in Viet Nam.

So today I’m going finally for my exam I asked for 18 months ago. I’m 78 years old. This is going
on and on and on. And I really have very little
faith, I like my providers at the VA MC and it’s in
Idaho, but I don’t like the bureaucracy in
Washington, D.C. that has a closed mind.

**MR. KNIFFEN:** Could I make a suggestion to you, sir?
I want to answer your question in two parts. The
first part is I’m trying to focus my comments today
on the NRC report and the work that the CAP is
trying to do. However, if you want me to address
your specific --

**MR. TOWNSEND (by Telephone):** No, you said you
weren’t trying to talk about what we’re talking
about.

**MR. KNIFFEN:** I don’t think I follow your last
point, sir.

**MR. TOWNSEND (by Telephone):** You gave more crap
about the NRC. That’s down the drain now.

**MR. STALLARD:** Okay, Tom, this is Christopher. I
think that what we have here is an opportunity with
Mr. Kniffen’s presence, and I appreciate the fact
that you have shared the difficult challenges that
you personally had to go through to get something
resulting ultimately today in Mr. Kniffen’s presence here.

And part of what we’re trying to accomplish as well is a commitment to move forward in partnership with the VA as the CAP has asked for a VA member to be part of the CAP. So I hear it in your voice, and you’ve had a long row to hoe here. And we’re appreciative as well that Mr. Kniffen is here. So we’re going to continue on and address what we can –

MR. TOWNSEND (by Telephone): Hey Chris, I’d like to have his phone number, his phone number and his fax number.

MR. STALLARD: All righty, we can do that.

Is that all right with you?

MR. TOWNSEND (by Telephone): Okay? Move on.

MR. KNIFFEN: I would like to finish what I was in the middle of saying. I feel even more interested in finishing my comment based upon your request for my phone number. I prefer to give you me e-mail address.

MR. TOWNSEND (by Telephone): I want your VA fax
number, Mister.

MR. KNIFFEN: I’ll give you my e-mail address, and
I’d like you to e-mail to me a summary of the
problems you’re having --

MR. TOWNSEND (by Telephone): Not a god damn e-mail,
Mr. Bureaucrat. You have a fax number and a number
at work. That’s what I want.

MS. BRIDGES (by Telephone): Chris, I think Tom is
just very flustrated (sic) right now. He cannot
hear very clearly. I can’t hear very clearly
myself. I think Tom is just so flustrated, he’s
just overwhelmed. That’s the problem.

DR. SINKS: Tom, this is Tom Sinks.

MS. BRIDGES (by Telephone): Is that right, Tom?

MR. TOWNSEND (by Telephone): No, the problem is
this guy that doesn’t want to do business is a VA
bureaucrat.

DR. SINKS: Tom, Tom, this is --

MS. BRIDGES (by Telephone): But you can’t hear very
well, can you?

MR. TOWNSEND (by Telephone): No, I can’t hear very
well.
MS. BRIDGES (by Telephone): Okay, I’m going to get off the phone and let y’all talk.

DR. SINKS: Colonel, this is Tom Sinks. Let me make a suggestion if I can. First of all just in general, I think a measure of success for the CAP has been to get Tom here. There was no obligation for the VA to show up or to be here. And, in fact, because of Tom Townsend and other people around this table putting some pressure on us and our writing letters and a bunch of interest, graciously the VA has come.

And, Tom, I would ask you to treat them graciously, not to intermingle your personal frustration with our representative here of the VA. I think, Tom, it makes a lot of sense if you would go ahead and send, if you, anything that you would fax to Tom instead if you would fax it to Perri. Perri can make a PDF of it, and we can send it by e-mail to the VA for you. We’re happy to do that.

And I know you know how to use a fax because I get them all the time.

MR. TOWNSEND (by Telephone): Why the hell can’t I
talk directly to the VA?

DR. SINKS: Tom, the CAP is not a vehicle to talk specifically to the VA, but --

MR. TOWNSEND (by Telephone): I’m a VA recipient.

DR. SINKS: Okay, but --

MR. TOWNSEND (by Telephone): I’m a disabled veteran. Who the hell else would I go to?

DR. SINKS: Tom, let’s separate the issue of you as a member from the CAP from you as dealing with the VA. I can’t speak for the VA. I certainly can’t speak for how the VA wants to interact with individual veterans. And I’m certain that plenty of them like yourself have frustrations.

But I think we want to keep, you know, if I remember this morning the session had to do with how does the CAP operate. And the first thing that I heard I think it was Jerry say is we don’t attack the people who are here. And I think it’s inappropriate to personally attack somebody who volunteers to show up.

MR. TOWNSEND (by Telephone): He volunteered to show up, but he won’t take --
DR. SINKS: Tom --

MR. TOWNSEND (by Telephone): -- he won’t provide any information about how to contact him at a later date.

DR. SINKS: Tom, I think the main point is that the VA would, I’m hoping would like to become more of our process and more of a mechanism of communication to help us in the bigger issue in terms of Camp Lejeune and perhaps be able to help you as an individual. What I heard from Tom was he was very willing to get your information. And for him it’s more efficient if he gets it by e-mail.

MR. TOWNSEND (by Telephone): Tom, look, the VA has known about this since 25 March. Here it is October, and one guy shows up finally. Oh, bloody god damn good deal. I should be grateful?

DR. SINKS: Tom, he isn’t here to specifically respond to the issue you’ve brought up with the VA back in your personal health issues. He’s here in terms of the CAP and Camp Lejeune. And I’d really like us to cut off the personal attack. So I’ve offered a mechanism for you to be in contact with
him. And I think if you can’t do it yourself on e-mail, we will facilitate it for you because --

MR. TOWNSEND (by Telephone): e-mail, Tom Sinks?

DR. SINKS: Tom, you can fax me. You know my fax number. We will translate anything you fax to us into a PDF and have it sent by e-mail to the VA for you.

MR. TOWNSEND (by Telephone): That’s very nice, but I don’t appreciate you being a conduit.

DR. SINKS: Well, okay, but I want to move on because I think I want to ask Tom a specific question because he mentioned a word I had not heard before which was presumptive service claim. And I think what the major issue here is how do we move from a situation from where people like Tom Townsend are trying to get an individualized service-related connection to --

MR. TOWNSEND (by Telephone): to have a god damned . ^ Agent Orange. ^ with Agent Orange and purple and green.

DR. SINKS: Tom, let me finish. I think the major issue here for us is, is the VA thinking about a
process by which they look at Camp Lejeune and what are the steps that are needed to move from where you are into a presumptive service connection where people from Camp Lejeune would qualify. And what is the thinking there and is there a role, how can the CAP remain informed about it or become involved.

MR. TOWNSEND (by Telephone): Well, let the messenger roll out the words then.

MR. ENSMINGER: Tom, I have a question.

MR. KNIFFEN: Can I answer his question? The question is, I brought up the concept of the idea of presumptive method to obtain service connection. And as I first explained there’s two approaches, and each one is statutory.

The first is the individual claim for service connection. The individual, could be me. I’m a veteran. I could say, I file a claim and say that I was injured or I became ill during my active duty, or in active duty for training and that today, three years after I left active duty or the reserves, I had a symptom or a diagnosis.

At that point on a factually, individually
process claim, I would have to go and get a CNP exam
or a private exam hopefully showing that there’s a
connection between my current diagnosis and what
happened in the service. And it takes some time to
do for a lot of reasons. The Veterans Claims
Assistance Act. There’s a huge volume of claims
now. Our claims, the numbers have gone up. I know
it’s not an excuse, but I’m just explaining it takes
a while.

The other method, it’s called Method B,
presumptive service connection. All you really have
to do is show you were in a certain place at a
certain time, and you have a diagnosis. The whole
nexus connecting part you don’t have to deal with.
Agent Orange is a perfect example.

Now, not every disease someone may allege or
currently have from service in Viet Nam is listed in
our categories for presumptive service connection.
But as I said Tuesday I believe, Tuesday was the day
that the press, I know it’s the day I saw it in the
“New York Times”. I think the press release was
issued Monday.
The Secretary, based upon this process that I described with the national academies, decided to add I think three, four new diseases to our list. If you go to the VA website, the press release from Monday is the lead press release and it lays out the details.

That’s what I mean by presumptive service connection. It’s faster. It’s easier, and it takes not nearly as much time to process.

DR. SINKS: But in this category B, and right now you have I think two areas. You have Agent Orange and Gulf War.

MR. KNIFFEN: Correct.

DR. SINKS: And the question to me is if there is, what is the possibility of moving the Camp Lejeune volatile organic compound issue into a potential third element of this presumptive service connection? What’s the process to getting it on the, even considering it?

MR. KNIFFEN: I understand your question, and we have other presumptive areas other than Agent Orange and Gulf War. I cannot represent what the chances
are. I have no idea. I cannot officially even present a guess as to what the chances are that this CAP or any other group could ultimately find a result whereby anything related at Camp Lejeune becomes presumptively service connected. I’m not authorized to do that. But even if I was, I have no idea at this time.

However, I can discuss the method, the route that is taken, and the route goes to the national academies. Because by statute we review the IOM reports that are issued by the national academies. Then we set up internal study groups made up of VHA, VBA, Office of General Counsel and our Office of Policy.

They read the report issued by the IOM. They may not recommend any additional disease or they may recommend one. They may recommend three. They may recommend three and the Secretary decides to go with four. It’s ultimately up to the Secretary. It’s a fairly lengthy process.

And so that is the road map, but the road map doesn’t always end in a disease being added as a
presumptive disease. Many times it doesn’t happen. We receive the Gulf War reports every year and study them carefully.

So, did that answer your question?

DR. SINKS: Yeah, I think so. I think what you were saying is by the mere fact that an NRC report or an Academy of Sciences report has been done on Camp Lejeune, it opens up the potential for consideration, that you don’t need an act of Congress to consider it, that because this report has been written it provides you the opportunity to consider it. I’m not sure if that’s correct.

MR. KNIFFEN: Yes, that’s exactly what I said.

DR. SINKS: Okay.

MR. KNIFFEN: Because speaking of this report in particular, the report only recommended 14 conditions and only categorized them as limited or suggestive evidence of association. Typically, those do not promote or develop into a recommendation to the Secretary. They’re not high enough on the list of five that I discussed earlier.

MR. BYRON: Mr. Kniffen --
MR. KNIFFEN: If I could just finish.

So even if they did, the internal VA working group, which I describe on page eight of our slides, would review that report from the national academies and make a recommendation. They may recommend no presumptives. They may recommend one. But ultimately it’s still by statute up to the Secretary.

So I don’t want to even suggest there’s any remote possibility that the NRC report could result in presumptive service connection.

I’m sorry, sir. I cut you off in mid-sentence. I apologize.

MR. BYRON: You’re fine. Is it doctor?

MR. KNIFFEN: Tom. No, I’m an attorney.

MR. BYRON: First off, we need to clarify a couple things. You’re here because who told you to come here?

MR. KNIFFEN: I’m here because --

MR. BYRON: Because of the NRC report?

MR. KNIFFEN: No, I’m here because Under Secretary Dunne, the Under Secretary for Benefits, told me to
come to the meeting.

MR. BYRON: Okay, and then, because I’ve been in contact as I told you with Dr. Brown, Dr. Brown with the VA since 2002. And I was always told that the VA, Veterans Affairs Committee and Armed Services Committees are the ones who need to direct the VA to be involved. Is that correct? Because that doesn’t sound correct.

MR. KNIFFEN: That sounds -- I couldn’t comment on that statement.

MR. BYRON: So now that you’re here, this presumption of disability, what we really need to do is get on with the final studies, don’t we, to have more of a chance to --

MR. KNIFFEN: I can’t comment as to what you need to do to increase your chances. All I can do is describe the process. We follow, when we adjudicate claims, whether it’s claim specific or on a presumptive basis. That’s all I can explain to you today.

MR. ENSMINGER: Is the VA aware that these lists of conditions that were covered by the NRC report are
only for perchloroethylene and trichloroethylene?

That the two known human carcinogens that were involved in the mixture at Camp Lejeune were omitted from their assessment of health effects, benzene and vinyl chloride, which were both present in the wells?

Now, it’s not our fault that the Marine Corps and the Department of the Navy never tested for those constituents in the final tap water while those wells were online. They were tested for those constituents after the contaminated wells were taken offline.

We know that these were present in the wells. The water modeling will show that, I’m quite sure. But the assessment by the national academy did not take those two known human carcinogens into consideration. That came out in the hearing the other day.

Furthermore, these folks did a literature review to come up with these lists and their findings, and I’m quite sure that there are studies out there, quite a few of them, that show non-
Hodgkins lymphoma as a cause from exposure to VOCs.

They left it off.

I also have some inside information that the new risk assessment, draft risk assessment for TCE is now going to declare TCE as a known human carcinogen, which is going to be released for public review the end of this month. What’s that going to do to this report?

And one more question. Why does the VA use the National Academy of Sciences, which is a dot org? It’s an organization. It’s not a governmental body. Why do you constantly go to them? Why don’t you use the EPA? Why don’t you use the National Institutes of Health, which are federal agencies? You’re a federal agency yourself. Why do you go to the National Academy?

MR. STALLARD: Are your questions done?

MR. ENSMINGER: Yes.

MR. KNIFFEN: We’re required by statute to use the national academies.

MR. ENSMINGER: Which statute?

MR. KNIFFEN: It’s a federal statute. We have no
choice in the matter. And as far as this report is concerned, we are bound to study this report and present recommendations to the Secretary of Veterans Affairs, to set up an internal committee to do this. We’re bound by statute to do that as I indicated.

The internal study group is composed of members selected by the Deputy Under Secretary for Health, for Benefits, Office of General Counsel, and the Office of Policy. They have not commenced their review. That report just came out a few weeks ago, month ago. We are following the statutory guidelines we follow on every single issue related to Agent Orange or the Gulf War or any other potentially presumptive condition.

**MR. ENSMINGER:** I’m not blaming you guys for this report by any means. But I just want you to know and be aware that there were some serious omissions and flaws in this report. And basically, the charge for this thing is written by the Department of the Navy. And you’re working with a flawed piece of junk right here, right now.

**MR. STALLARD:** So the question I have then is if
you’re bound by statute to do it in this way and
look at this report, are you able to look at any
other information in that process or is it strictly
that report?

MR. BYRON: And as an example, Tom, my daughter has
aplastic anemia. If you look in a medical
dictionary under aplastic anemia, it says 40-to-70
percent of all cases are caused by exposure to
benzene. So this is, I think, why Jerry’s asking.
Is this the only thing you’ll look at when assessing
Camp Lejeune or will there be, I guess, you know,
since there were omissions as far as documentation
before they wrote their report, will that be a
chance to be brought up and, I guess, discussed in
your committee meetings? Thank you.

MR. KNIFFEN: We’re statutorily required to follow
the report -- not follow the report, but make it our
primary source of consideration. However, internal
study is conducted by a committee that’s made up of
epidemiologists such as some of the gentlemen
sitting here. They bring their expertise to the
table.
I’ve sat in on some of the meetings on other subjects to talk about other studies. But I have to emphasize that when we follow the National Academy’s work product, whether it’s the NRC or the IOM, we’re doing what the statute requires us to do.

MR. ENSMINGER: Where did your statute come from that requires you to use the NAS?

MR. KNIFFEN: It’s a federal statute, federal law.

MR. ENSMINGER: Federal law. It’s congressional?

DR. SINKS: First off, let me answer part of Jerry’s question which I think actually applies to all of our federal agencies, Jerry, which is that many of us, because we are federal agencies and there’s often a question about transparency within federal agencies, go to the National Academies of Sciences for advice.

And it’s very common for all of us as federal agencies to use that resource to give us independent advice, not advice bound by us as federal agencies. So that’s typical. We may not like what this report is, but I’ll also describe that the relationship between the VA and the IOM on the Agent Orange issue
I think has been a very productive, transparent process.

Let me ask Tom a question which is, is there a fundamental difference here between this NRC report which was charged by the Department of Defense, for the Department of Defense charged the NRC to provide that information versus the relationship that you have with the IOM for Agent Orange? Is that a process where you had a standing committee that actually the VA has charged to provide information versus this non-standing committee which gave a one-time report to the Department of Defense?

**MR. KNIFFEN:** I’m not sure about the Department of Defense part, but I know that there’s a statute unique to Gulf War and Agent Orange to follow regarding the national academies.

**DR. SINKS:** But it’s your, your charge, you fund --

**MR. KNIFFEN:** Correct.

**DR. SINKS:** -- you fund the committee, and you charge the committee.

**MR. KNIFFEN:** Well, we don’t charge the committee.

We follow the statute, which requires us to go to
the national academies.

**MR. PARTAIN:** But who tells the national academies what to do?

**DR. SINKS:** The standing committee has a charge which actually you work with, VA works with the IOM to create whatever that charge is. The charge on the NRC was a, the NRC report, which was a, not a standing committee but a one-time report, was a charge that was developed because of the statute by Congress asking DOD to do it, but was specific to the Department of Defense’s needs.

It was different fundamentally than the relationship you have with the IOM and that committee.

**MR. KNIFFEN:** I think the answer’s probably yes, but when you use the word charge, I’m not sure I exactly follow what you mean. But we have an ongoing statute that we follow with regard to the Gulf War and Agent Orange.

**DR. BOVE:** Right, but you don’t have one for Camp Lejeune.

**MR. KNIFFEN:** Correct.
DR. BOVE: And the IOM charge is in the law itself --
using that term charge. It’s in the law itself.
So the charge given to the NRC was not to come up
with a list of, or not to come up with a list of
compensatory, presumptive -- what’s the word,
preemptive. What is that term? I had it written
down, presumptive service connection; that’s it.

But to answer questions that the Department of
Defense had concerning Camp Lejeune and what to do
in the future. So it’s a very different situation
actually. Now, that’s one thing --

MR. KNIFFEN: I don’t know that -- first of all, I
have to say that when you use the word charge, I’m
going to have to back off that because I’m just not
prepared or knowledgeable what exactly you mean.

DR. BOVE: If there’s no legislation --

MR. KNIFFEN: Please let me finish. And I cannot
say that the IOM is charged to make recommendations
on what should be presumptive and what shouldn’t be.
What they do is provide a ranking, the one-through-
five listing, which I made reference to before,
which is set out in this report. That’s as far as
they go. Do you follow what I’m saying?

So I don’t want, please don’t read too much
into what I’ve said about presumptives. Don’t over-
evaluate those comments I made.

**DR. BOVE:** I’m making a distinction because at Camp
Lejeune the legislation that asked for the NRC
report did not ask for a one-to-five listing.
That’s something NRC took on itself. Whereas, the
Agent Orange and Gulf War probably did ask for such
an exercise. That’s one difference.

But I have another question. So there are five
levels. The first level is sufficient evidence for
causality. So any disease there probably make it to
the -- if we were talking about Agent Orange now --
any in that box probably ended up with going on your
presumptive service connection list. The second
level is sufficient evidence for an association, a
statistical association. That’s the second one.

The third level is limited or suggestive
evidence of a statistical association, and the
fourth level is insufficient evidence to determine
whether a statistical association exists. The fifth
level is limited evidence against an association, I guess. I can’t remember what the fifth one was. So that’s how it’s layered.

Now, and Jerry was pointing this out, some of those listed by the NRC report as having limited or suggestive evidence for an association should be bumped up at least one level to be consistent with previous NRC reports. And for TCE and kidney cancer, if the EPA draft risk assessment stands, there is sufficient evidence of causality. So that would be bumped up two levels.

So this is a fluid situation. I think with Agent Orange you had to base a lot of your work on studies of veterans. There was some information about agricultural use of these herbicides and had some information from them as well. But most of the information probably came from -- correct me, Dick, if I’m wrong here -- on studies of Viet Nam vets itself.

At Camp Lejeune we’re very far away yet from coming up with any definitive, any results from our studies. I shouldn’t say the word definitive. And
this chart is really based on occupational data for
the most part. They did look at the drinking water
studies. They didn’t like any of them. I disagree
with their assessment, but that’s, -- none of the
drinking water studies really entered into this.
This is pretty much occupational data, a very
different kind of exposure scenario or at least
somewhat different than the scenario at Camp
Lejeune.

So this is going to change as more occupational
studies get done. It may change based on our
studies, and then there are other drinking water
studies that may happen in the future. So do you
revisit this? I mean, how does it get revisited? I
guess that’s the long --

MR. KNIFFEN: I need to, I cannot even comment on
what you just said because you’re crossing over the
area of policy into medical science and the studies.
And I think I know where you’re going, but I’m just
not qualified to respond. And I’m not trying to
avoid answering your question, but you’re moving
into an area that I don’t, I’m just not qualified.
DR. BOVE: How does the VA update its information?

MR. KNIFFEN: We receive reports every year on the Gulf War and Agent Orange every single year, and they’re available for free on the website.

MR. PARTAIN: Like with the IOM, would the VA be capable of going to the NAS and asking for an IOM review of VOC exposures? Granted that this NRC report which seems from what I’m hearing is taking greater weight on everything --

MR. KNIFFEN: I don’t know the answer to your question. I don’t know.

MR. PARTAIN: If we’re identifying that there’s a problem, obviously, there are people coming to the VA asking for assistance.

MR. KNIFFEN: Well, they’re asking for assistance, again, I recommend you not over-focus on my comments regarding presumptive service condition. They’re asking for assistance on filing claims for disability benefits, individual claims primarily.

MR. PARTAIN: Yeah, there are people coming to the VA saying I was exposed at Camp Lejeune. I have XYZ disease, whatever, and I’m asking for assistance
through the VA for the medical coverage and
disability or what have you. Would the VA not then
go to IOM and ask for a review on VOC exposures? It
seems to me that there’s just a blanket well, you
weren’t harmed because this is what the NRC report
said that was commissioned, that was released this
year.

MR. KNIFFEN: I don’t know the answer to your
question. It hasn’t come up. I don’t know the
answer.

MR. PARTAIN: So I mean, what would trigger the VA
to start --

MR. KNIFFEN: I can’t answer that question. That’s
a policy matter that I’m not prepared to answer
today.

MR. PARTAIN: Okay.

DR. SINKS: I’m going to try my hands at
interpretation. Let me know if you think I’m, any
of you let me know if you think I’m off base. The
good news that I’m hearing because I want to put
this into good news and maybe some other news as
well.
The good news that I’m hearing is that there is attention in the VA office on Camp Lejeune, and they’ve started a process by which to evaluate this on a broader scope than just individuals. The not-so-good news is they have a report right now that perhaps many of us aren’t as comfortable with to use. That doesn’t mean it’s the only report they will ever use, but that’s what they’ve got.

So I’m hearing kind of a balanced presentation, if you will, which is that there is attention at the highest levels of the VA that Camp Lejeune is an issue that is appropriate to be looking at because you’ve formed some type of review group to look at this. That they have what they have, and you can’t comment on what they have, which is this NRC report. And that in some ways this will likely be a fluid situation that may change over time.

MR. KNIFFEN: I would respond this way. As I said at the bottom of page eight of my chart, page eight, that we have a work group being convened at the highest level, policy level, to review the report. So that should indicate the level of interest.
MR. BYRON: Mr. Kniffen, one thing when you go back that you might want to express is that through all these reports that have been done, documentation has been kept from those people who were writing these reports. So we now have a public health assessment that’s been torn down because documentation was kept from that report. There was an EPA criminal investigation that I’m sure they’re not aware of the benzene exposure.

Do you think, Jerry?

MR. ENSMINGER: Oh, I know it.

MR. BYRON: Then there was the Commandant’s supposed independent panel report which had an Assistant Commandant of the Marine Corps on it. Can you see our concerns? And then we had this NRC report that comes out that the Marine Corps continually states that they were aware of the benzene exposure, which is totally untrue, totally untrue.

And this is why I think there’s so much hostility in the room sometimes, and even those individuals that are on the phone. And I don’t, it might have been personally directed toward you, I
don’t think that that’s really what he wanted to do. I think he is frustrated, and hopefully, you won’t go back and also be frustrated and say that these people are crazy and, you know, don’t send another representative to the CAP.

Because what we really need to do is show the VA that over here is one individual who is getting compensation for his injuries at Camp Lejeune. We already know this. We know there’s individuals out there that have received compensation. And then there’s other individuals that are receiving no compensation. We’re trying to figure out how this determination was made over here and then this one’s denied over here.

We’re not understanding that because number one, we didn’t think anybody was being looked at from Camp Lejeune with the VA. You’re the first person who’s showed up. I’m still trying to figure out exactly who’s directed, I mean, I know the Secretary directed you. And I’m sure that it was spawned by Senate --

MR. ENSMINGER: The hearing.
MR. BYRON: -- and hearings and CNN reports to get someone here today. But what I really need to know is will there be continued VA involvement here at the CAP, if you know that?

MR. KNIFFEN: I will certainly recommend it. I don’t make that decision. I was told to come here today, and I will report that I had a totally positive experience here. I’m serious.

MR. ENSMINGER: And that would be a lie.

MR. KNIFFEN: I didn’t say that. He did.

And that the give and take of information is what we’re looking for because it ultimately helps veterans, and I’m going to make that recommendation.

MR. PARTAIN: Tom, one thing I want to point out and kind of piggyback on what Jeff was saying. Last week at the hearing during the question-and-answer session, Dr. Nuckols, apparently Dr. Savitz didn’t want to have anything to do with hearing in truth, not to show up, but Dr. Nuckols was there on behalf of the NRC report.

And when Senator Burr was questioning him as he sat next to me concerning how and whether or not
they evaluated benzene and vinyl chloride in their final product, he started to go into and stated that they were relying on what ATSDR had done, and that ATSDR’s concern was PCE and TCE. And then stopped himself mainly because of the public health assessment.

The benzene/vinyl chloride issue was not addressed in the 1997 ATSDR public health assessment and that document was withdrawn. The NRC report was commissioned while that document was available. The direction they took was based on that document, by Dr. Nuckols’ own admission. And then the report was issued two months after the public health assessment was withdrawn.

So the report was structurally based on a flawed piece of science that had to be withdrawn, and therefore, there’s some grave concerns with the validity of the report. So that’s one of the things that we’re trying to articulate to you and to the VA.

Because like I said, from what I heard earlier -- and I’m not a veteran so this doesn’t directly
affect me -- but for all these people out there, if
the VA’s relying on this NRC for guidance, you’re
following a roadmap that is flawed. And to put this
in a real-time perspective, there are people out
there -- and this is why I’m sitting here -- that
have been affected by this, that need VA help.

Phil Huntley, I’ll put a name out there, in
Iowa whose family’s being ruined. He has a terminal
condition called central nervous system vasculitis.
Basically, his blood vessels in his brain are coming
apart. He’s had 43 strokes in two years before the
age of 49. He’s been denied VA benefits. He’s lost
his job, lost his medicals. He’s in a nursing home
now in Iowa, an Iowa veterans nursing home Jerry
mentioned earlier.

Those are the things we’re dealing with. Those
are the real people we’re dealing with. One of the
male breast cancer cluster gentlemen, he’s stage IV,
metastatic cancer to his bones. And hopefully, he
will beat the odds, but they’re not in his favor.
He has no medical coverage, and he’s on disability.
Those are things, those are the real-time things
that people are needing help from the VA.

And that’s why I wanted to articulate my concerns about this NRC report being the catch-all right now which it seems to me that’s what everyone’s leading to.

MR. BYRON: You actually did a better job than me.

MR. PARTAIN: And I’d just ask you to go back and review the hearing part during the question-and-answer session where Senator Burr is questioning Dr. Nuckols, and then I follow up, jump in there after he had stopped and so kind of finished it for him.

MR. STALLARD: We’re coming toward the end of the day. I would like to thank Mr. Kniffen for being here. We had some, I guess what we will need to know for the next meeting is will you provide us feedback once you return about a VA representative to join the CAP?

MR. KNIFFEN: I’ll find out very quickly for you.

MR. STALLARD: I appreciate it. Thank you.

And that will be communicated how?

MS. RUCKART: I can receive e-mails from him so you can e-mail me and I can share the news.
MR. STALLARD: Okay, very good.

MR. PARTAIN: And thank you, Tom, for coming.

MR. BYRON: I did want to ask one last question.
I’m sorry. There is proposed legislation as you
know for veterans of Camp Lejeune and also dependent
family members. And I know you may or may not be
able to answer this question, but what would be the
mechanism if there was to be help from the VA for
families, for veterans and dependent family members?

What is the avenue or is there an avenue with the VA
for dependent family members just so the people that
are listening might know?

MR. KNIFFEN: I can’t comment on pending or proposed
legislation for which we’ve not issued official
views through OMB. That’s just a standard, hard-
and-fast rule. I expected you were going to ask
about pending legislation today, but that’s the
answer I have to give you.

MR. BYRON: May I ask you this? Is there any --
I’ll hold that for another meeting. Thank you.

MR. PARTAIN: My understanding is when Congress
passes legislation saying there is a presumption of
service connection, then the VA is bound to follow that because it would be law. And then they would go, from what I read here, then they would go to IOM and try to get the medical diagnosis that would be connected to that service connection.

MR. BYRON: I understand that, but what I was getting at is in the past I’ve been told that there’s no avenue for dependent healthcare through the VA. I don’t know if that’s correct or not. I’ll hold that until another time.

MR. STALLARD: So I guess we’re at the point where we need to talk about the next meeting. Is that correct?

MS. RUCKART: Just a general wrap up as well.

MR. BYRON: I did have one other issue to bring up as far as notification to the veterans that are being notified by the Marine Corps and so forth. You know, we asked for the Commandant’s cooperation for a second letter concerning the water survey, health survey.

I noticed I could only get an answer of the highest office possible, but as soon as the NRC
report came out, they sent out some propaganda in my opinion, but they sent out what was basically the summary of the report which was telling people, you know in my estimation, don’t worry. You’re not going to get sick. And right at the top of the letter is the Commandant’s Office.

So I don’t understand why we can’t get commitment from the Commandant’s Office to send out the follow-up letter to participate in the health survey for Camp Lejeune. And I’d like to have that answer by the next meeting in writing by the Commandant if that’s possible.

**MS. SIMMONS:** I’ll bring it forward.

**MR. BYRON:** Okay, thank you.

And then the other question on that issue is when individuals are registering with the Marine Corps website, the Public Affairs Officer there is telling them that they’ve got nothing to worry about. I don’t believe that’s true, and we have several examples. I’ll provide the e-mails to you on that, and I’m going to start asking those people whose names those people are --
MS. SIMMONS: They should not be saying that.

MR. BYRON: -- because if they are saying that, somebody should be bringing ^ minimum against them. They got no business putting in their bias. We’re talking about bias in reports and so forth, and for somebody to come up and say to a veteran or his family member that you don’t have anything to worry about what happened at Camp Lejeune, first off, they don’t know that because I don’t know that. And I’ve been following this for ten years, and we’re still waiting to see that through these studies. So I want that corrected.

MR. STALLARD: Yes?

UNIDENTIFIED SPEAKER IN AUDIENCE: This at Camp Lejeune?

MR. BYRON: Yes.

UNIDENTIFIED SPEAKER: Do you have an e-mail?

MR. BYRON: I’ll get the e-mails for you. Can I get a card?

(Whereupon, multiple speakers spoke.)

MR. MENARD (by Telephone): Chris, could I bring up a suggestion?
MR. STALLARD: Yes, Tom.

MS. RUCKART: Allen.

MR. STALLARD: Allen or Tom?

MR. MENARD (by Telephone): Yes, yes. Has the Marine Corps used the avenue of the VA Department to go into all these local veterans offices for them to use their lists of people that were stationed at Camp Lejeune to get a hold of them as far as being, you know, exposed to the toxic water?

MR. STALLARD: I’m not sure I understand the question so what we’d like to know is has the VA used the local offices to reach out to the veterans they serve?

MR. MENARD (by Telephone): Has the Marine Corps used the VA to get a hold of these people because I’m sure all the local offices can go through their list of all the Marines that were, that are actually registered in that county or that state or whatever how they use it. Have they used that avenue?

MR. STALLARD: Mary Ann?

MS. SIMMONS: We’ve worked with a lot of different veterans’ organizations at affairs, different
places, so in terms of getting a specific list of names, no. But we’re doing wide publicity. We just provided another update of ways we’re trying to get the word out. Do you guys post this on your website?

**MR. PARTAIN:** We’ve been posting the breakdown by state and for that particular document right there, it doesn’t have any letterhead on it, so we haven’t posted it, no. You talking about the...

**MS. SIMMONS:** It’s just the notification update, and this is the summary of the Camp Lejeune outreach as of 7 October ’09, just different things that’s going on.

**MR. BYRON:** We can.

**MR. PARTAIN:** Yeah, we can put that on.

**MS. SIMMONS:** It might be a good idea.

**MR. BYRON:** Yeah, we’ll put that on.

I did have one more question for Tom. At the hearing that was last week, the VA representative, I think incorrectly, thought that they had the list of the registrants for Camp Lejeune, 144,000 I believe it is. Is that correct?
MR. KNIFFN: One hundred and forty-six thousand.

MS. SIMMONS: Yeah, 146,000.

MR. BYRON: And I think he indicated that they did have the list because they were asked if there was a cross-reference to that list and individuals coming into the VA. And I believe he said they had the list, but the Marine Corps even there indicated that, no, they don’t have the list.

So I’d like if that’s possible for the Marine Corps or DOD to provide that list of the 146,000 to the VA, and if possible, present this to the Secretary as can they do a cross-reference to see how many of these veterans are actually.

MR. KNIFFN: I just don’t know the answer to your question, but I can take it with me.

MR. BYRON: That’d be great.

MR. KNIFFN: Sure.

MS. SIMMONS: I don’t know. I would think there might be privacy issues. I don’t know. I can ask the question.

MR. PARTAIN: During the hearing Senator Burr asked them to do that, and I think they’re working on
getting that done.

MR. GAMACHE: Yeah, it has to be approved. There are some federal statutes that there’s some notification requirements ^ federal agency. But it can be done.

MR. BYRON: (Inaudible)

MR. GAMACHE: No, I’m unsure of the process so I can’t really comment on how long it would take.

MR. STALLARD: Is there some way that someone will have their finger on the pulse for that so that by the next meeting we have some sort of update there was progress or no progress or action, no action? Who could be that person?

MR. GAMACHE: (Inaudible)

MS. SIMMONS: We can note to the next meeting.

MR. TOWNSEND (by Telephone): They know how to ask questions of the VA.

WRAP-UP

MR. STALLARD: We’re about ready to wrap up here. We need to think about our next meeting which is where we’d either have to be right after the new year I’m guessing at this point or right before.
MS. RUCKART: Don’t look at me. I’m not going to be here.

MR. STALLARD: I know. We won’t have the services of --

MS. RUCKART: If you wait for me to get back, you’ll be planning on meeting in April.

MR. STALLARD: So what time frame are we looking at?

MR. PARTAIN: January.

DR. BOVE: Well, that would be the earliest. Well, the issue would be to meet to find out what happened with the funding. By January we’d know something. We really do know something then that would make sense. We probably would also, there’s something, the mortality study should be, hopefully, would be started.

MR. STALLARD: Morris would have his stuff finished.

DR. BOVE: Yes, Morris would have, hopefully, have -- - I’ll speak for Morris.

MR. MASLIA: I’ll speak for Morris.

DR. BOVE: I’ll speak for Morris. No, go ahead, Morris.

MR. MASLIA: By January we will definitely have,
much sooner than January, an ATSDR position on what modeling approach or approaches we will be taking. Again, that will be determined by exposition paper that we’re writing, reviewed through the hierarchy through ATSDR and then presented to a small group, three or four, experts, not the huge expert panel, but experts to comment or give us feedback on. And so by January we will have done that.

We will also have hopefully by January the Chapter C, the data reports of the installation restoration program sites published and online. And hopefully, the underground storage tank sourcing data in a draft form of a report for people to be reviewing.

**MR. STALLARD:** So Morris is definitely on the agenda for the next meeting with a lot going on in his arena.

**MS. RUCKART:** I know what’s going to happen. I know when the next meeting is going to be. It’s going to be my second day back in the office just like it was last time I came back from maternity leave. So I’ll predict you’re going to have it mid-to-end February
so I can hit the ground running as soon as I get back.

**MR. MASLIA:** Perhaps we should have an alternate location like Hawaii or some warm place.

**MR. STALLARD:** That question has come up. We could be closer to our VA colleagues if we go to Washington, D.C.

**MR. MASLIA:** It’s sort of cold in D.C.

**MR. STALLARD:** Okay, so clearly we’re not going to decide then right here, right now. What we’re going to look at is toward mid-to-late January, early February. Is that all right?

**MR. PARTAIN:** I think we probably should stay in January now.

**MR. STALLARD:** Okay, January, I hear a bid for January. Certainly, when the funding is verified, before then I’m sure you’ll all know. The e-mail will go out.

**MS. HARRIS:** The CAP funding that we have would cover this meeting and one more already.

**MR. STALLARD:** Okay, good.

**DR. BOVE:** In Washington, D.C. maybe.
MS. RUCKART: Yeah. That’s very difficult to ^.

DR. BOVE: Well, actually we do have a D.C. office.

MR. STALLARD: We do.

MS. RUCKART: But there’s more funds involved, there’s more funds involved because there’s more travel involved for more people.

MR. STALLARD: We could have a CAP meeting at Camp Lejeune, you know.

DR. BOVE: No, we’ve already nixed that idea.

MS. RUCKART: ^ and the airport.

DR. BOVE: Well, play around with --

MR. ENSMINGER: ^ the airplanes.

MS. RUCKART: I have a request from Jeanette. She asked me to let you know that when you submit your vouchers, please use the travel expense form that’s in the envelope, the postage-paid envelope. I just wanted to pass that on.

MR. STALLARD: We did things a little different this time. Thank you for coming up with your own operating guidelines and principles and adhering to them for the most part. Be prepared next time. We want to make this a little bit more informational
sharing as we did this time, but you’re going to
tell us what have you done personally to contribute
to the CAP, what activities are going on. What’s
going on in your world relative to the CAP.

And, again, we’re very thankful, if not
grateful, that you were here with us today
representing the VA. Thank you for taking the
barrage of emotion that came with that being the
very first representative.

MR. KNIFFEN: I was happy to be here.

MR. STALLARD: It gets better.

So unless there’s anything else, that adjourns
our meeting for today, and I thank you all for
coming and wish you a safe journey home.

(Whereupon, the meeting was adjourned at 3:00 p.m.)
CERTIFICATE OF COURT REPORTER

STATE OF GEORGIA
COUNTY OF FULTON

I, Steven Ray Green, Certified Merit Court Reporter, do hereby certify that I reported the above and foregoing on the day of Oct. 14, 2009; and it is a true and accurate transcript of the testimony captioned herein.

I further certify that I am neither kin nor counsel to any of the parties herein, nor have any interest in the cause named herein.

WITNESS my hand and official seal this the 19th day of November, 2009.

-----------------------------
STEVEN RAY GREEN, CCR, CVR-CM, PNSC
CERTIFIED MERIT COURT REPORTER
CERTIFICATE NUMBER: A-2102